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BACKGROUND: Parkinson’s disease is the commonest 
neurodegenerative illness affecting the world population. Autonomic 
dysfunction  and  non-motor symptoms (NMS) in Parkinson’s disease 
(PD) are frequent, disabling and reduce quality of life of patient. The 
prevalence of insulin resistance might play a role in the etiopathogenesis 
of Parkinsonism. 
AIM AND OBJECTIVE: There  is  a  paucity  of  studies  on  
autonomic dysfunction in PD in Indian population. The study aimed to 
evaluate  cardiac autonomic activity in Parkinson’s disease patients with 
HRV parameters and study the prevalence of insulin resistance in 
Parkinsonism and correlate the findings with duration of Parkinson’s 
disease.   
MATERIALS AND METHODS: We evaluated autonomic 
function in 30 diagnosed patients of Parkinson’s disease (age 40-70 
years) and 30 healthy age & sex matched controls by  Resting Heart Rate 
Varaibility and evaluated insulin resistance by measuring serum insulin 
levels with ACCUBIND Insulin test system. The results were analysed 
with SPSS version 17. Both the results were correlated with each other 
and with the duration of disease.  
RESULTS:  Statistically significant reduced HRV and both 
sympathetic and Parasympathetic failure have been found in Parkinson’s 
disease patients when compared to age and sex matched controls. The 
prevalence of insulin resistance is also significantly high in Parkinson’s 
disease. A significant negative correlation was found between the LF 
(ms2),HF (ms2) values and duration of disease in this study. 
CONCLUSION: Abnormalities of autonomic function  and  
prevalence of insulin resistance were integral and present across all the 
stages of PD patients which may be associated with the adverse cardiac 
events. Early recognition and treatment of these may decrease morbidity 
and improve quality of life of PD patients. 
KEYWORDS: Autonomic dysfunction, Parkinson’s disease, 
Heart Rate Variability, Insulin resistance. 
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1.INTRODUCTION 
 “A good stance and posture reflect a proper state of mind” 
       -MORIHEI VESHIBA 
  “Involuntary tremulous motion, with lessened  
  Muscle power, in part not in action and even 
  Supported, with a propensity to bend forward and 
  to pass from a walking to running pace, the senses and  
  intellects being uninjured”  
                    - JAMES PARKINSON 
 
Therefore, Tremor, rigidity coupled with bradykinesia are the 
characteristic  features of  Parkinson’s disease which is the one of the 
common neurodegenerative illness affecting the old age of the world. It 
affects both men and women. The average age of onset is about 60 years. 
But cases have been reported even at late twenties. 
  The incidence rate of Parkinson’s disease worldwide varies 
from 4.9 to 26 per 100000. (Mac Donald et al 2000; Rajput AH et al 
1984) 1&2 The incidence of Parkinson’s disease increases with ageing.  
It is estimated that prevalence will increase dramatically in future 
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decades. Henceforth, the world is in a critical position to find a disease 
modifying strategy for Parkinson’s disease to alleviate the problem of 
increasing prevalence. 
Patient can be considered to have Idiopathic Parkinson disease 
when they have bradykinesia and at least one of the following signs : 
rigidity, tremor, gait disturbances or postural instability with no other 
known causes. (Daniel and Lees 1993).54 
The clinical features like resting tremor, rigidity, bradykinesia and 
gait impairment are considered to be dopaminergic features. Additional 
clinical features such as speech difficulty, autonomic disturbances, mood 
disorders, sleep dysfunction, cognitive impairment and dementia are 
considered to be non-dopaminergic features.  
The neuropathology of Parkinson’s disease is found to be 
degeneration of dopamine producing and secreting nerve cells in the 
extrapyramidal brain structures  and  deposition of α-synuclein in the 
nerve cells. It also affects many regions of brain apart from basal ganglia  
and the neuropathology of Parkinsonism  also affects the central and 
peripheral autonomic nervous system. (Baraak H et al 2003, Blaszczy JW 
et al 1998, Lozza A et al 1997)4,5,6 
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In addition to that the disease also extends into the peripheral 
autonomic nervous system involving sympathetic ganglia, cardiac 
sympathetic afferents and the myenteric plexus of  the gut. (Pospisil et al 
2008, Jankovic J et al 2008) 7,8  Recent studies suggest that the non-
dopaminergic clinical features could precede the imminent clinical 
manifestations of  Parkinsonism. (Santa Maria J et al 1986, Ponsen MM 
et al 2004,5,6).9,10  
A healthy human heart doesn’t beat at regular rate. It shows 
variation from one beat to the next. The heart rate is being greatly 
influenced by external and internal stimuli and regulated by autonomic 
nervous system. This variation of heart rate between the successive beat 
is called as Heart Rate Variability which bears a close relationship to 
sympathetic and parasympathetic nervous system. Heart rate variability 
indices are utilized worldwide for the assessment of cardiovascular risk in 
individuals including bradyarrhythmia, tachyarrhythmia, angina, 
myocardial infarction and hypertension.  
Heart rate variability is a non – invasive and very useful tool in 
detecting cardiovascular autonomic disturbances. Autonomic dysfunction 
becomes one of the cardinal clinical feature of  Parkinson disease  
including the manifestations like perturbation in cardiovascular 
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regulation, orthostatic hypotension, hyperhydrosis, defects in 
pseudomotor function etc . (Valko PO et al 2012, Trachani E et al 2012, 
Sauvageot  N  et  al  )11,12,13  Many Parkinsonism disease patients show 
autonomic disturbances during the early course of illness in addition to 
motor symptoms. Changes in the cardiovascular disturbances can be 
easily detected by HRV indices even in the early phase of disease. Early 
detection and management of sympatho –vagal imbalance using HRV 
indices in time and frequency domain reduces the mortality rate in 
Parkinson’s  patients. 
Thus HRV is a non-invasive tool not only for research but also for 
early detection of complication and timely management in Parkinsonism 
disease patients. (Pursiainen  et al 2002 )14 
Insulin, a peptide hormone secreted by beta cells of pancreas 
regulates the body response to store energy after a meal. Serum insulin 
concentration increases in a direct proportion to glucose concentration. 
Aminoacids  and ketoacids can also stimulate its secretion. (Ganong 22nd 
edition)69 Moreover, the secretion of insulin is under the neuronal control, 
and the anticipation of meal or thought of food stimulate insulin secretion 
without the presence of glucose by activating the parasympathetic 
pathway. 
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The brain was thought to be an insulin independent organ for a 
longtime.  (Healy   DG  et  al  2004  )149 But, insulin receptors are richly 
expressed throughout the brain in neuronal and glial cells which suggest 
that a role of insulin in cerebral function. ( Abbott MA et al 1999, 
E.Ferrannini et al 1999, R.J. Schuling kamp et al 2000) 150,151,152  Thus,  
Insulin an ancient hormone with its novel role is vital for proper 
functioning of brain and it seems to play an essential role in  the 
regulation of neuronal proliferation, apoptosis, synaptic transmission and  
neuronal degeneration .   
Eventhough insulin and insulin receptors are present throughout 
the brain, they are densely present in hippocampus, hypothalamus, basal 
ganglia and frontal lobe. Chronic hyperinsulinemia and insulin resistance 
or reduced insulin sensitivity may have a negative influence on neurons. 
Many studies have revealed the fact that insulin resistance is highly 
prevalent in Parkinsonism disease patients. (Craft & Watson, 2004 ).17 
In Parkinson’s disease, high prevalence of abnormal glucose 
tolerance, chronic hyperglycemia,  abnormal insulin levels and  insulin 
resistance potentiates the progression of neurodegeneration which in turn 
accelerates autonomic dysfunction, motor and cognitive impairment. 
(Boyd et al 1979).16  
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 Animal studies have thrown light to the hypothesis that there is an 
essential role for insulin to regulate the functions of  dopamininergic 
nerve  cells  of  brain.  (Craft  &  Watson  2004  )  17Chronic hyperglycemia 
and hyperinsulinemia resulting from insulin resistance  ends in oxidative 
stress  and  the  production  of  oxygen  free  radicals  out  of  the  above  
mechanism  may potentiate  the  degeneration of  dopaminergic nerve 
cells. (Saller & Chiodo 1980, Stanahan et al 2008 ).18,19 
Thus, chronic hyperglycemia, hyperinsulinemia becomes one of 
the risk producing agent for the onset at early age and rapid progression 
of Parkinson’s disease. Since the association between the insulin 
resistance  and neurodegeneration have become evident recently, 
knowledge of the specific mechanisms relating insulin dysregulation and 
neurodegenerative diseases may allow the development of drugs to 
decelerate neurodegeneration in future. 
Therefore, current study was taken up with the aim of assessing the  
cardiac autonomic activity in patients with Parkinsonism disease by 
analysing  HRV parameters  and to estimate the insulin resistance by 
evaluating  serum insulin levels and  as compared with normal controls.  
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2. REVIEW OF LITERATURE 
 Parkinson’s disease is the commonest disabling neurodegenerative 
illness affecting the old age of the world’s population, occurs in all ethnic 
groups and all socio economic classes which is characterised by 
impairment of voluntary movement, rigidity, tremor. It has been called 
“Happy disease” because of the characteristic stooped posture and 
chaplinesque shuffling.(Kelly 1995) Parkinson’s disease is increasingly 
common disease of elderly patients, increasing the morbidity of old age 
and imposing challenge to the Physician community. Information on the 
pathophysiology and treatment strategies of Parkinson’s disease are  so 
voluminous. This review offers a glimpse into the rich history regarding 
Parkinson’s disease. 
 Since the current study is concerned with the changes in HRV 
parameters  and autonomic dysfunction brought about by Parkinson’s 
disease and prevalence of insulin resistance in Parkinson’s disease 
patients by evaluating serum insulin levels, the literature pertaining to 
Parkinson’s disease, abnormalities in HRV and Insulin resistance alone 
are reviewed.  
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2.1.  PARKINSON’S DISEASE 
 The clinical features resembling those of Parkinsonian illness has 
been explained in several study sources like an Egyptian Papyrus, an 
ayurvedic medical treatise, the Bible and  Galen’s writings. There are no 
references related to Parkinson’s disease after Galen until the 17th 
century. Several authors including Sylvius, Gaubius, Hunter and Chromel 
described about the elements of disease in 17th and 18th century. (Garcia 
Ruiz PJ 2004, Lansk JK 2010, Koehler PJ  1997)153,154,155 James 
Parkinson, English Physician explained the clinical features of disease as 
Paralysis Agitans in his book “An Essay on the Shaking Palsy”. 
 In 1881, contributions by Jean Martin Charcoat were a milestone in 
the understanding of disease and he renamed the disease as Parkinson’s 
disease in honour of James Parkinson. Lewy body which is a 
pathognomonic of  Parkinson’s disease was first described by Frederic 
Lewy in 1912. Studies of Arvid Carrison and Oleh homykiewicz on 
neurotransmitter dopamine revealed the underlying biochemical changes 
of  Parkinson’s disease in 1950.  
 Anti cholinergic drugs and surgery (lesioning of the corticospinal 
pathway and basal ganglia) were the only treatment for Parkinsonian 
illness till the discovery of  Levodopa by Casimlin Funk. Deep brain 
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stimulation entered the clinical practice as a possible treatment by the  
late 1980s.The main component of Lewy body was found to be  
α-synuclein  in 1997. 
2.2.  CLASSIFICATION 
 Parkinson’s disease belongs to G-20, 21, 22, 23 of ICD-10.22 
 This classification was approved by the International Conference 
for the 10th revision of the International Classification of Disease in 1989 
adopted by the forty third world Health Assembly.22 
2.3.  EPIDEMIOLOGY 
 Parkinsonism is the one of the common neurodegenerative illness 
disabling old age of the community. It affects several million people of 
the population of the world. It affects   0.6% of people living  in the 
industrialized countries. The Prevalence rate of Parkinson’s disease 
ranges between 18 to 418 per1 lakh . ( Zhang Zx, Roman GC 1993 )23  
The Prevalence rate of Parkinson’s is more common in the elderly and it 
is rare before 50 years of age. The Prevalence of Parkinson’s disease 
increases   2  times  in  those  over  60  years  of  age   and  10  times  in  the  
population over 80 years. 
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 A community based study  performed on epidemiology of  
Parkinson’s disease in the  Kolkota city, India  found prevalence rate of 
Parkinsonism as 52.85/1,00,000 and incidence rate as 5.71/1,00,000 per 
year. (Das SK et al 2010)156 One prospective cohort study in Italian 
population found a two-fold increased risk of Parkinson’s disease in men 
compared with women. (Balderschi M, Di Carlo A et al, 2000 )24 Male 
predominance and rural living are closely correlated with increased 
Prevalence of Parkinson’s disease. (Martilla RJ, Rinnie UK, 1976 )25 It is 
found that there will be increased risk of Parkinson’s disease in persons 
exposed to pesticides and reduced risk with smoking. Parkinson Day has 
been celebrated on 11th April on the account of increasing awareness 
among  the  public.  A  red  tulip  is  chosen  as  the   symbol  of  the   disease  
which represents James Parkinson, a Dutch horticulturalist.26    
2.4.  ETIOLOGY 
 The aetiology of Parkinson’s disease remains obscure and 
idiopathic Parkinson’s disease is common in most of the people affected. 
However, 10-15% of Parkinson’s disease cases are inherited .(Moore 
DJ,West AB et al 2005; Hattori N, Mizuno Y 2004; Mcnaugt, Olanow ) 
27,28,29 Recent concepts have implicated environmental toxin as possible 
etiological  agent  of  Parkinsonism   disease  in  persons  who  have  been  
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rendered susceptible by their genetic profile or advancing age. (Tanner 
CM 2003)30 Though many toxins, occupation, microbial organisms have 
been reported to have an association with Parkinsonian illness, none have 
been proved to be an etiological agent. Recent genetic and experimental 
evidences have suggested that defects in ubiquitin proteosome system 
play a essential role in the pathogenesis of both familial and sporadic 
forms of Parkinsonian illness. (Petrucelli L, Deeivson TM,2004)31 
2.5.  ENVIRONMENTAL FACTORS 
 Several environmental factors such as MPTP (1-methyl-4-Phenyl-
1,2,3,6- tetra hydro pyridine ), exposure to pesticides, well water drinking 
and rural living have been linked to development of Parkinsonism in 
patients. (Tanner CM, Goldman SM 1996; Seidler A, Hellenbrand  
W 1996)32,33 MPTP, a street drug contaminant can cause human 
Parkinsonism. Post-encephalitic Parkinsonism resulting from Endemic 
encephalitis lethargica sets an example of infectious disease as a 
causative factor of Parkinson’s disease. Studies have revealed that 
negative association of smoking with the development of Parkinson’s 
disease.  (Gorell  JM,  Rybicki  BA  et  al  1999)  34 The incidence of 
Parkinson’s disease has been reported to be inversely related to the 
following: Frequency of bowel movements, coffee drinking, alcohol 
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consumption, hypertension, head trauma. (Ross GW,Abbott RD et al 
2000; Benedetti MD, Bower JH et al 2006 ; Paganini – Hill A 2001)36,37,38 
2.6.  GENETIC FACTORS 
 There is strong association between increased risk of development 
of  Parkinson’s disease and positive family history especially in patients 
with early onset Parkinsonism. Around 10% of people with Parkinson’s 
disease possess a first degree relative with the clinical features of 
Parkinsonism. About 6% of people are known to have Parkinson’s 
disease which may  occur due to mutation of one of the specific genes. 
(Tanner CM,Goldman SM 1996; Taylor CA,Saint-Hilaire MH et al 
1999;Rybicki BA,Johnson CC et al 1999; Rocca WA,MC Donnell SK et 
al 2004) 32,40,41,42   
GENETIC MUTATIONS IN PARKINSON’S DISEASE 
2.6.1.      PARKIN MUTATIONS 
 Autosomal recessive juvenile Parkinsonism is found to be resulting 
from  a mutation in the gene coding for the protein called Parkin. It is 
characterized by Parkinson’s disease of very early age at onset of average 
26 years. The mutation in the Parkin gene which is a 465AA/52 KDa 
protein includes deletion, multiplication and point mutation. (Matsumine 
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H et al 1997; Mizuno Y,Hattori N et al 2001)44,45  The Parkin gene is 
diffusely expressed in the cytoplasm, nucleus, Golgi and neuronal 
processes. (Horowitz JM et al 2001).46 It is not clear precisely how Parkin 
mutations lead to neurodegeneration. However, it likely relates to a loss 
of ubiquitin ligase activity and a reduced capacity to label misfolded 
substrate proteins for proteosomal degradation. 
2.6.2.   UCH-L1 MUTATIONS 
 There is mutation in the gene Ubiquitin C terminal Hydrolase-L1 
which is associated with a familial form of Parkinsonian illness and 
characterized by people presenting with early age at onset about 49-51 
years. It clinically resembles sporadic form of Parkinson’s disease and 
which responds  to Levo-dopa therapy effectively .(Leroy E et al 1998)47 
2.6.3. α - SYNUCLEIN MUTATION 
 α -Synuclein protein is expressed throughout the central nervous 
system especially in pre-synaptic terminals, lipid membranes and  
ventricles. (Goedert M 2001) 47  α -synuclein mutation leads to a clinical 
picture resembling those of idiopathic Parkinsonism presenting at early 
age  and a high occurrence of dementia. 
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2.6.4.     DJ-1 MUTATION 
 Park 7 is a protein which in human is encoded by Park 7 gene also 
known as  DJ-1.  It  contributes  1-2  % of  early  onset  familial  Parkinson’s  
disease cases which is characterized by early age of onset around mid 
thirties, slow rate of progression, good L-Dopa response, presence of 
dystonia and psychiatric disturbances. 
2.6.5.   PINK 1 MUTATIONS 
 PINK 1 mutations are associated with Autosomal recessive pattern 
of inheritance, early age of onset of Parkinsonian disease in which 
patients present clinically at their 32-48 years, slow progression and good 
response to L-dopa.49 
2.6.5.  LRRK2 MUTATIONS 
 LRRK2 gene codes for a protein called Dardarin, a Basque word 
for tremor. An Autosomal dominant form of Parkinsonian illness has 
been linked with mutation in the gene coding for LRRK2 (Leucine Rich 
Repeat Kinase2) associated with the loss of dopaminergic  nerve cells in 
striata nigra pars compacta and few cortical lewy bodies. 
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2.7.  NEURONAL ORGANIZATION OF BASAL GANGLIA 
 Basal ganglia are the deep nuclei of the cerebrum which includes 
Caudate nucleus, Putamen, Globus Pallidus,substantia Nigra and 
subthalamic nucleus located on each side of brain. The Basal ganglia do 
not receive input from spinal cord. But they receive most of their input 
signals from the cerebral cortex. Their action on the motor area of cortex 
is mediated through thalamus. (Nakano K, Kayahara T et al 2000) 50  
  The essential role of Basal ganglia in control of voluntary motor 
activity includes cognitive control of motor activity, timing and scaling of 
intensity of movements, subconscious execution of movements. 
2.7.1. CONNECTIONS & OPERATIONS OF BASAL GANGLIA  
 Neurons of striatum begin to discharge before any movement 
which suggests that these neurons help to select the movement that is to 
be made. Activity in the Putamen is related to the occurrence of 
movement  of  body.  Activity  in  caudate  nucleus  is  related  to  eye  
movement. Most regions of cerebral cortex project topographically 
 to striatum with the exception of primary visual and auditory cortex. 
(Berne & Lewy ) 52 
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 The corticostriate projections arise from neurons in layer V of 
cortex. The striatum influences neurons in the ventro anterior & ventro 
lateral nuclei of thalamus by 2 pathways – direct and indirect. The 
ultimate effect of Direct pathway through the Basal ganglia to motor 
cortex results in enhancement of  the motor activity. The overall effect of 
indirect pathway is to reduce the motor activity.  
 Dopamine is the major neurotransmitter of the neurons of 
substantia nigra Pars Compacta of the basal ganglia. The release of 
dopamine in nigrostriatal tract results in stimulatory  action on direct 
pathway and an braking action on the indirect pathway. This is due to the 
action of dopamine on different types of receptors that are found in the 
internal segment of Globus pallidus (D1 receptors which are excitatory in 
nature) and in the external segment of the Globus Pallidus (D2 receptors, 
inhibitory  in  nature).  The  overall  effect  of  release  of  dopamine  in   the  
above two scenario is a enhancement of activity in the motor areas of the 
brain. (Berne & Lewy)52 
2.8.  PATHOPHSIOLOGY  
 Parkinson’s disease most commonly occurs due to idiopathic 
degeneration of nigrostriatal system of dopaminergic neurons. It is also 
found that there is greatly diminished activity of dopamine secreting  
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nerve cells caused by neuronal death in the Pars compacta region of 
substantia nigra. There is an imbalance between excitation and inhibition 
in the basal ganglia created by the loss of dopaminergic inhibition of the 
Putamen. The resulting increase in inhibitory output to the external 
segment of globus pallidus decreases inhibitory output from the 
subthalamic nucleus, and this increases the excitatory output from this 
nucleus to the internal segment of globus pallidus. This in turn increases 
the inhibitory output from this segment to thalamus, causing a  
reduction in excitatory drive to cerebral cortex. (Berne & Lewy; Adam  
& Victor) 52,53 
2.9.  DIAGNOSTIC CRITERIA 
 Criteria from UK Parkinson’s disease Brain Bank and US National 
Institute of neurological disorders & stroke require slowness of 
movement plus either one of the following signs and symptoms: rigidity, 
resting tremor or postural instability. Other possible causes for these 
symptoms have to be ruled out. (Daniel  SE, Lee AJ 1993)54 
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Figure 1 : NEURONAL ORGANISATION OF BASAL GANGLIA 
AND PATHOPHYSIOLOGY OF PARKINSON’S DISEASE 
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2.10.  HOEHN AND YAHR SCALE 
 The Hoehn and Yahr scale is widely used clinical rating scale 
which measures the severity of motor impairment in Parkinson’s 
disease.92 
1:  Only one sided involvement, usually with minimal or no functional 
disorders 
2:  Both sided or midline involvement without affecting the balance 
3:  Both sided disease: mild to moderate disability with diminished 
postural reflexes; physically independent  
4:  Severe disabling disease; still able to walk or stand without any 
assistance 
5:  Confound to bed or wheelchair unless aided 
2.11.  MOTOR SYMPTOMS IN PARKINSON’S DISEASE 
 The cardinal features of Parkinson’s disease are bradykinesia, 
tremor and rigidity. The patient is unable to initiate the voluntary 
movements (akinesia) or the voluntary movements are decreased 
(hypokinesia). Difficulty in initiating movement is because of 
hypertonicity of muscles. Manifestations of bradykinesia include: delayed 
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motor initiative as evidenced by prolonged reaction time, slow 
performance of voluntary movements, mask like facies, absence of 
normal associated movements, shuffling or festinant type gait in which 
patient is bent forward and walks quickly with short steps as if trying to 
catch up centre of gravity or preventing himself from falling, retropulsion 
i.e. when a walking patients is suddenly pulled backwards, he begins to 
walk backwards and is unable to stop. (Adam & Victor) 53 
2.11.1. RIGIDITY 
 Rigidity refers to increase in tone of the muscles. It occurs due to 
increased tone in both the protagonist and antagonist muscles. Mainly 
large proximal group of muscles are affected. Usually there occurs 
uniform resistance to flexion giving a feeling as if lead pipe is being bent 
(lead pipe rigidity). Sometimes there is a series of catches during passive 
motion  of  limbs  (cog  wheel  rigidity).  It  is  because  of  rigidity,  posture  
becomes that of flexion attitude in which back is flexed, arms are 
abducted and flexed and the knees are bent. In advanced cases, the 
rigidity may increase to such an extent that s statue –like appearance is 
produced with complete absence of movements. (Harrison, Adam & 
victor)53,55 
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2.11.2.   TREMORS 
 Tremors, (i.e. involuntary rhythmic oscillatory movements of distal 
parts of limbs and head) seen in Parkinson’s disease have following 
characteristics: The tremors are present in the  resting state, but disappear 
on  initiation  of   activity.  It  is  Hallmark  of  Parkinson’s  disease  and  so  
popularly known as resting or static tremors. Frequency of tremor ranges 
from 4 - 6 times/sec. It is frequently seen as pill-rolling movements of the 
hand, i.e., rhythmic contraction of thumb over first two fingers. Tremors 
are suppressed during sleep and exaggerated by stress, anxiety and 
excitement. The tremors are observed as rhythmic movements of 
pronation and supination in fingers, hands, lips or tongue. The  tremors 
seem to occur due to pacemaker activity in the nucleus ventralis 
intermedius of thalamus. Thalamic neurons exhibit an intrinsic auto-
rhythmicity and probably get unmasked due to increase in the inhibitory 
input from the pallidum. (Harrison , Adam & Victor )53,55 
2.12.  NON MOTOR SYMOTOMS IN PARKINSON’S DISEASE 
 Non-motor clinical manifestations in Parkinson’s disease includes 
disorders of cognitive function , sleep wake cycle, regulation of mood, 
function of autonomic nervous system, sensory system function and pain 
modulation.  
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 In addition to dopaminergic nigrostriatal system, neuropathology 
of Parkinson’s disease also involves the mono-aminergic neurons of 
locus ceruleus, dorsal vagal nucleus, hypothalamus, limbic cortex and 
peripheral autonomic nervous system. Hence, non motor symptoms 
become more prevalent and prominent during the course of disease. 
(Braak H, Del Tredici K et al 2003; Blaszczyk JW 1998) 4,5 
  Non motor symptoms of Parkinson’s disease act as early or 
preclinical biomarker of Parkinsonian illness in an otherwise 
asymptomatic individuals as evidenced from clinical studies performed  
to assess the  olfactory dysfunction or REM sleep disturbances.  
(Ponsen MM, Stoffers D et al 2005; Stiasny – Koloster K, Magerl W et al 
2005 )10,56 
2.12.1.   SENSORY SYMPTOMS 
 Parkinson’s disease patients experience numbness, tightening 
sensation, tingling sensation, diffuse pain, neuralgic pain, burning 
sensation. Pathophysiology underlying  these sensory symptoms is 
probably resulting from altered central pain pathway as a part of the 
neurodegeneration, absence of dopaminergic pain inhibitory input to the 
dorsal horn synapse, absence of noradrenergic descending pain inhibitory 
input from the locus ceruleus to the dorsal horn of the spinal cord and 
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widespread cortical lewy body degeneration . (Buzas B, Max MB2004) 
57,58 
2.12.2.   OLFACTORY DYSFUNCTION 
 It has been established from a number of studies that olfactory 
dysfunction i.e. impairment in odour detection, discrimination, and 
identification is an early clinical sign in 90% of Parkinson’s disease 
patients. (Katzenchlager R, Zijlmans J et al 1999).59  
2.12.3.  NEUROPSYCHIATRIC DYSFUNCTION 
 Neuropsychiatric features such as mood disorders, cognitive 
dysfunction and complex behavioural disorders are associated with 
Parkinson’s disease in contrary to J.Parkinson’s original descriptions 
about “the senses and intellect being uninjured”. (Adam & Victor )53 
2.12.4. SLEEP DISORDERS 
 Sleep disorders including difficulties in sleep initiation , increased 
number of awakenings during sleep, muscle cramps,  dystonia or 
nocturnal motor manifestations such as difficulties in moving in bed, 
motor restless leg syndrome, nocturnal bladder incontinence, nocturnal 
mood disorders, hallucination and day time sleepiness are the most 
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frequent non-motor clinical manifestations in patients with Parkinsonian  
disease. The neurodegeneration of the Parkinson’s disease affecting the 
sleep structure, respiratory disturbances are the various mechanisms 
suggested for sleep dysfunction in the Parkinson’s disease patients. 
(Tandberg E, Larsen JP et al)60 
2.12.5. AUTONOMIC DYSFUNCTION 
 Autonomic disturbances  has been reported in Parkinsonism 
patients by James Parkinson.  Clinical features of derangement of both 
the central and peripheral autonomic nervous system could be seen in 
Parkinsonism. Presence of  α-synuclein within the sympathetic ganglia 
and antibodies to sympathetic nerve cells in Parkinsonism has been found 
recently. α-synuclein could be detected in the higher autonomic centres 
including the hypothalamus, dorsal vagal nucleus and intermediolateral 
nuclei of thoracic cord.Presence of Lewy bodies within the central and 
peripheral autonomic nervous system has been believed to be a biomarker 
for neuronal loss. 
 Autonomic dysfunction becomes the prominent  universal feature 
of the Parkinson’s disease that includes orthostatic hypotension, 
constipation, sialorrhea, seborrhoea, hyperhydrosis, heat intolerance, 
urinary and sexual dysfunction. Studies have found evidence for 
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cardiovascular dysfunction in 30% of cases, urogenital dysfunction in 
32% of cases and gastro intestinal dysfunction in 36% of cases. 
(Magalhae M et al 1995) 61 
 Most of the people suffering from Parkinsonism initially present 
with autonomic disturbances supporting the hypothesis that these 
autonomic disturbances might act as a predictive  biomarker in 
Parkinsonism. 
CARDIOVASCULAR AUTONOMIC DYSFUNCTION 
 Symptomatic orthostatic hypotension is a late feature of the 
Parkinsonian illness and Peripheral symptomatic cardiovascular 
denervation is prominent in Parkinson’s disease patients. Cardiovascular 
Autonomic dysfunction is highly prevalent in patients with bilateral 
severe bradykinesia and rigidity. (Spiegel et al 1969, Martilla et al 1974, 
Happaniemi 2003)62,63,64 
GASTRO INTESTINAL DYSFUNCTION 
 Neuropathology of Parkinsonism affecting the peripheral 
autonomic nervous system also affects the myenteric plexus  and results 
in the formation of Lewy body in the colonic autonomic plexus leading to  
subsequent colonic sympathetic denervation. Studies have found either 
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constipation or increased transit time in as many as 80% of Patients with 
Parkinsonian illness.(Jost WH,1997)65 
UROGENITAL DYSFUNCTION 
 Urogenital dysfunction such as difficulties in erection , difficulty in 
ejaculation, increased  frequency of urine, urgency of micturition, 
incomplete bladder evacuation, double urination and urging incontinence 
becomes the late feature of Parkinson’s disease. 
2.13.      HEART RATE VARIABILITY 
Heart Rate Variability represents the variability of both 
consecutive heart rate and consecutive RR intervals. The other terms of 
Heart Rate Variability used are cycle length variability, Heart period 
variability, RR interval variability, RR interval tachogram. The 
regulatory mechanisms of Heart Rate Variability takes its origin  from 
sympathetic and parasympathetic nervous system and thus Heart Rate 
Variability can be used as quantitative bio marker of autonomic nervous 
system. (Task Force 1996)66   Stress, certain cardio vascuar diseases, and 
other pathological conditions have a profound influence on HRV. 
(Berntson,1999) 67,68 
 
27 
 
2.13.1.  AUTONOMIC NERVOUS SYSTEM 
 Langley,  an  English  Physiologist   who  first  coined  the  term  
“AUTONOMIC NERVOUS SYSTEM” in 1898 to describe the part of 
nervous system which deals with the functions occurring automatically 
without the knowledge of Individual. The Autonomic Nervous System 
controls the functions of the involuntary organs of the body such as heart, 
blood vessels, exocrine and endocrine glands and all visceral organs. The 
Autonomic Nervous System responds to endogenous and external stimuli 
and a constant internal environment (Homeostasis) is maintained by 
Autonomic Nervous System. It regulates visceral activities, coordinates 
body’s response to stress and regulates the endocrine system. (Ganong 
2012)69 
 Based on their anatomic, functional and neurochemical properties, 
the two divisions of Autonomic Nervous System are the  Sympathetic 
and Parasympathetic Nervous System. The Parasympathetic and 
Sympathetic divisions are inturn  divided into Preganglionic and 
Postganglionic neurons.   
 The Parasympathetic preganglionic neurons have their cell bodies 
in the brainstem and in the II, III, IV sacral segment of spinal cord. Their 
axons come out of the CNS via the cranial and sacral spinal nerves and 
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synapse with postganglionic neurons in the specialized ganglia close to 
the visceral organ. The vagus nerve originating from the dorsal vagal 
nuclei and the nucleus ambigus in the medulla oblongata carries the most 
widespread cranial parasympathetic output.(Loewy and Spyer 1990)70 
The cell bodies of sympathetic preganglionic neurons are located 
in the intermediolateral horn of thoracolumbar segment of the spinal 
cord. Their axons reach the Para vertebral ganglia of the sympathetic 
trunk and synapse with the post ganglionic neurons. 
Almost  all  the  organs  of  our  body  are  innervated  by  both  
sympathetic and Parasympathetic nerves. These sympathetic and 
parasympathetic nerves are usually acting in a reciprocal manner. But, in 
some organs the sympathetic and parasympathetic nerves act 
synergistically to regulate the visceral function. (Benorroch 1997,  
Crick et al 2000)72,73 
The neurotransmitter in all parasympathetic neurons is 
Acetylcholine. Nor adrenaline is the primary neurotransmitter in 
sympathetic postganglionic fibres exceptions are  those cholinergic fibres 
innervating the sweat glands and some cholinergic vasodilator fibres. 
(Willis WD 1993, Benarroch 1997)71,72 
29 
 
The frontal lobe cortex, the limbic cortex, the amygdala and the 
hypothalamus are the main CNS structures controlling the Autonomic 
Nervous System. (Willis 1993) 71  The highest level of integration of 
Autonomic Nervous System function appears to be the frontal lobe 
cortex. The limbic system regulates autonomic response to emotional and 
affective expressions. The hypothalamus serves as the most important 
regulator of Autonomic Nervous system that integrates the cortical 
autonomic structures of the preganglionic autonomic neurons. 
2.13.2.  CARDIAC AUTONOMIC ACTIVITY 
 The Autonomic Nervous system regulates many of the functions of 
cardiovascular system through its two branches sympathetic and 
parasympathetic. Both heart and vascular system are innervated by 
sympathetic and parasympathetic nerves. The parasympathetic nerve 
(vagus) supplies SA node and conduction system of heart. Sympathetic 
nerves mainly innervate the cardiac muscle and vascular system. The 
sympathetic branch of Autonomic Nervous system increases the cardiac 
action and the parasympathetic branch of Autonomic Nervous system 
slows the cardiac action. (Benarch 1997, Crick et al 2000) 72,73 
The autonomic nerve supply of heart is controlled by cardiac 
autonomic centres situated in the medulla which form the integrating 
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centre of cardiac autonomic reflex. Rostral ventral Lateral Medulla also 
known as vasomotor centre regulates the cardiac sympathetic nerves and 
excites the heart. The cervical sympathetic nerves form the efferent limb 
of cardiac autonomic reflex. 
 The nucleus ambiguus also called as medullary parasympathetic 
centre or cardiac vagal centre receives afferent from various peripheral 
organs and in turn sends inhibitory output via vagus nerves to decrease 
the heart rate and force of contraction of heart. Some inputs exciting the 
cardiac sympathetic centre will inhibit the parasympathetic centre. There 
is  an  antagonist  effect  of  these  both  vital  centres  on  each  other.  
(Berne &Lewy)52 
When the vagus nerve is stimulated, there will be release of 
Acetylcholine into all of the organs except the adrenal glands. The 
acetylcholine released into SA node results in decrease in heart rate 
through the opening of channels in the cell membrane that are permeable 
to K+ but not Ca2+. So, K+ moves out of the cell without this inward flow 
of Ca2+ and postsynaptic cell is inhibited which slows down the Heart 
rate. (Burnstock 1986, Sakman B, Noma et al1983)75 
 Heart has its own inherent activity generating its own impulse at 
constant rhythmic intervals which is seen as spontaneous firing of 
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Pacemaker cells in the wall of Right atrium. These Pacemaker cells are 
small round cells with few organelles that are connected by large number 
of gap junctions. (Ganong 2012)69 
 The autonomic inputs of heart are mediated by SA node and AV 
node which are responsible for cardiac rhythms. SA node being the 
primary Pacemaker of heart, initiates an electrical signals which in turn 
begins the pumping action of heart. Then, the signal passes through the 
AV node which spreads the electric signals throughout the ventricles of 
heart by specialised conduction pathway. 
 
Figure 2 :  INNERVATION OF  HEART 
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 The intrinsic firing rate of uninnervated SA node is 100 beats per 
minute. (Ganong 2012)69 The sympathetic system increase the rate of 
depolarisation of SA node in the innervated heart, while the 
parasympathetic system through the vagus nerve decreases the firing rate 
of SA node. The net accelerating and decelerating effects of the cardiac 
sympathetic and parasympathetic system will determine the cardiac 
sympathetic and parasympathetic tone respectively. 
 The resting vagal tone dominates over the sympathetic tone that 
makes the heart rate below 100. The heart rate is conventionally 
measured by number of beats per minute. The duration of cardiac cycle 
of all heart beats occurring in one minute, even under resting condition is 
not the same. There is beat to beat variability of R-R interval in 
milliseconds. This spontaneous beat to beat variation is known as Heart 
Rate Variability. (Task Force 1996)66 
The physiological  origin of  HRV is  the fluctuations of  activity of  
cardiovascular vasoconstrictory and vasodilatory centres in brain. Usually 
the fluctuations are due to baroreflex mediated BP oscillations, circadian 
rhythm and thermoregulation. All these factors influence the length of  
R-R interval. The original balance between their activities keep on 
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changing constantly in order to achieve maximum considering of all 
internal and external stimuli. (Task Force 1996)66 
 Higher the HRV represents the optimal balance between the 
sympathetic and parasympathetic nervous system. The higher the HRV, 
the quicker the heart adapts to external and internal stimuli and better the 
individual react to all these stimuli. 
Depressed HRV primarily means that Heart rate is monotonously 
regular which indicates the depressed activity of Autonomic Nervous 
system to cope up with the internal and external stress. A low HRV 
represents a diminished ability to external environment and may suggest 
serious health problem. HRV is a measure of the Respiratory Sinus 
Arrhythmia (i.e.) the heart rate increases during inspiration and the heart 
rate decrease during expiration. This normal phenomenon decreases with 
age and also under stressful conditions.(Wheeler&Whatkins 1973, Kahna 
& Gik 1975, Eckeberg 1983) 76,77,78  
 The Respiratory sinus arrhythmia is recorded as fluctuations in the 
RR intervals within the frequency range 0.15-0.4 Hz which are 
considered to be mediated mainly by vagus. The Heart Rate Variability is 
found  to be the quantitative biomarker of parasympathetic function from 
the previous animal studies and human studies using atropine also shows 
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that Heart Rate Variability is a marker of Parasympathetic 
function.(Broutia and Nowak,1939; Berntson et al 1994)68,79 
Heart Rate Variability can easily detect changes in body stress, 
while other physiological parameters are still in “normal” accepted range. 
Some Heart Rate Variability changes may act as a first sign of distress 
which reflect involvement of energy dependent sympathetic system.(Task 
Force 1996)66 
The parasympathetic (vagal) influence is dominant and heart  rate 
variations depend on vagal modulation; however, the sympathetic and 
parasympathetic branches continuously interact. The SA node is rich in 
acetyl cholinesterase, the enzyme breaks down acetylcholine  which 
allows for rapid but brief effects from the parasympathetic activation. 
 Acetylcholine is released from the vagus nerve and binds with the 
muscarinic receptors on the SA node cells.(Ganong 2012) 69  Sympathetic 
activation also releases Acetylcholine in the preganglionic fibres, but 
most of the sympathetic postganglions, including the adrenal medulla, 
release epinephrine and nor epinephrine. Nor Epinephrine binds to beta-1 
receptors and increases the heart rate by increasing Ca2+ permeability. 
The parasympathetic response is faster than sympathetic, likely because 
stimulation of the muscarinic receptors reduces the amount of nor 
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epinephrine released during sympathetic activation and also due to a 
cholinergic withdrawal of the adrenergic stimulus. (Task Force 1996) 66 
 In a healthy person,  autonomic tone,  allow for a  constant  level  of  
balance and a great range of control and adjustment of heart rate. Some 
adjustments in the heart rate can be made to respond to demands of active 
tissues in the body. In a person with good vagal tone, epinephrine and nor 
epinephrine  are  almost  continuously  released  in  small  amounts,  even  at  
rest. 
  Since the parasympathetic division is dominant at rest, the heart 
rate is controlled and a balance between the parasympathetic and 
sympathetic stimulation is negotiated. Several studies have concluded 
that an increased activity of  sympathetic and decreased vagal modulation  
increase the risk of ventricular tachycardia, ventricular fibrillation and 
sudden cardiac death.(Martins 1985; Pozzati et al 1996; Schwartz et al 
1992) 80,81,82 
2.13.3. HRV AS A AUTONOMIC FUNCTION TESTING TOOL 
 The evaluation of autonomic disorders is more widely readily 
available with evolution and validation of reliable non invasive 
techniques. The techniques used to study the autonomic functions are 
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described of which cardio-vagal, adrenergic and pseudomotor function  
are  most common methods involved. 
The most commonly used test of autonomic function depends on 
changes in heart rate, blood pressure in response to breathing and to 
posture changes. These tests are simple, non invasive, easy to perform and 
are both sensitive as well as specific. The fact that variability of heart rate 
occurs because of autonomic innervations of SA node has been exploited 
to develop tests that stimulate this autonomic supply and results in 
variability of heart rate. 
2.13.4. HEART RATE VARIABILITY TEST  
 There has been no quantitative marker for cardiovascular 
autonomic functions. Studies in last 30 years have shown a great 
association between Autonomic nervous system (ANS) and 
cardiovascular morbidity, including sudden death in arrhythmias .(Lewy 
et al 1994)83 
 Heart rate variability represents the hall mark of such markers. 
Automated measurement of Heart Rate Variability (HRV) is possible 
with the use of many commercial devices nowadays. But the precise 
measurement and assessment of HRV analysis being more complex, 
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European society of cardiology and North American society of pacing 
and electrophysiology have contributed a Task Force to appropriate 
standards. The guide lines and recommendations of Task Force 96 are 
followed in this study. “Heart Rate Variability” has been the universally 
accepted term to explain the  variation of both consecutive heart rate and 
R-R  intervals,  which  emphasizing  the  fact  that  it  is  the  period  of  time  
between two consecutive beats that is being analyzed rather than the heart 
rate per second.(Task Force ,1996) 66  Heart Rate Variability is a non-
invasive electrocardiographic marker reflecting the action of sympathetic 
and vagal component of Autonomic Nervous system on heart. It reflects 
the total amount of variations of both instantaneous heart rate and RR 
interval. 
 The clinical use of HRV was well recognized when Hon and Lee 
in 1965 found that, alteration in HRV precedes fetal distress before any 
significant variation occurred in heart rate itself.86 
  During 1985 Ewing et al performed simple test for short term R-R 
difference in the  detection of diabetic neuropathy.86 Akselrod  et  al  
(1981) was  the  first  person  to  explain  about  power  spectral  analysis  of  
heart rate fluctuation for quantitative evaluation.85 
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 Juan sztajzel et al 2004, noted that among the various available 
non invasive techniques to assess  the sympathovagal balance, heart rate 
variability has evolved as a simple non invasive tool to evaluate 
autonomic status at sinoatrial node.87 
 Sayers et al (1973) noticed alteration on existence of physiological 
rhythm imbedded in beat to beat   heart rate signals.88 Stein  P.K.  et  al  
(1994) proposed that the heart rate variability is a non invasive 
electrocardiographic marker which represents the activity of sympathetic 
and parasymapathetic component of ANS on sino atrial node of the 
heart.89 Persson et al (1983) computed that the R-R interval variation 
(RRIV),  as  assessment   of  the  heart  rate  variability  and  one  of  the  
simplest and most reliable test used for the evaluation of the PNS 
autonomic functions of the heart.90 
 Heart Rate Variability (HRV) is mediated primarily by at least 
three primary mechanisms: 
· Vagal feedback from pulmonary stretch receptors 
· Central medullary coupling between pulmonary and 
cardiovagal neurons 
· Arterial baroreflex induced oscillations. 
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 The resting Heart Rate Variability which comes under the grouped 
cardiac autonomic function tests which evaluate the cardiac division of 
the ANS i.e both sympathetic and parasympathetic in resting state. 
2.13.5. COMPONENTS OF HRV 
Beat to beat variability present even in resting condition. 
Parasympathetic tone  dominates in the resting state and  the vagal 
modulation primarily influences the variation in heart rate period  greatly. 
There is a constant interaction of vagal and sympathetic activity.  
 The R-R interval variation existing in the resting state represents 
optimal tuning of the beat to beat control mechanism.(Askerold et al 
1985; Saul JP et al 1990) 88,91,97 
 There is excitation of  vagal afferent activity and inhibition of 
sympathetic efferent activity resulting from vagal afferent modulation. 
The stimulation of sympathetic afferent activity mediates the opposite 
reflex effects. (Schwartz et al 1973; Malliani1982)82,96 Efferent vagal 
activity is believed  to be tonic restraint by cardiac afferent sympathetic 
activity. The both sympathetic and vagal efferent activities directed to 
sino atrial node are best explained  by discharge greatly synchronous with 
each cardiac cycle that can be modulated by central autonomic centres  
and respiratory centers and peripheral oscillators (fluctuations in arterial 
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pressure and respiratory movements).( Malliani et al 1991) 96    All these 
oscillations results in  generation of rhythmic fluctuations in efferent 
neural discharge which is seen as short and long term oscillations in the 
cardiac cycle.  
 Evaluation  of these rhythms influences on the state and function of 
(Task force, 1996). 
 The central  autonomic Oscillators 
Ø The sympathetic and parasympathetic efferent activity 
Ø Humoral factors 
Ø Sino atrial  node.  
 
2.13.6. CLINICAL APPLICATIONS OF HRV 
 HRV has been a non invasive test for assessing the autonomic 
functions in various clinical conditions, including diabetes mellitus, 
hypertension, angina pectoris, cardiac failure and recently used as a 
screening tool in patients with obstructive sleep apnea. Altered HRV is a 
warning sign of diabetic neuropathy and precedes the clinical 
manifestations. It predicts the mortality risk after MI, arrhythmias. It can 
be used for exercise training in the field of sports physiology.  
(Task Force 1996 )66 
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2.13.7. CURRENT LIMITATIONS OF HRV 
 Inspite of the the large number of research studies, the 
measurement of HRV is still used in research fields and not routinely 
used in therapeutics. It may be due to non- availability of standard values, 
cost of equipment and software, variability of HRV parameters with age, 
gender, drug interferences and concomitant diseases.(Task Force,1996) 66 
2.13.8. HEART RATE VARIABILITY INDICES IN PARKINSON’S 
DISEASE: 
 M.kalio, T.Happaniemi et al (2000) studied cardiovascular 
autonomic reflexes and Resting  Heart rate variability parameters  in 50 
patients with untreated Parkinsonism  and compared with 55 normal 
controls to study the cardiovascular changes as a predictive marker of 
autonomic  nervous system dysfunction in patients with untreated 
Parkinsonism illness. They found HF and mildly the LF were decreased 
and both sympathetic and Para symapathetic hypofunction has been 
reported. They reported significantly diminished HRV, significantly 
reduced  BP reaction to tilting in their study. The patients presenting with 
hypokinesia/rigidity have much reduced HRV than patients presenting 
with tremor was revealed from their study.100 
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 Goldstein DS, Holmes C et al (1997) found an attenuation in the  
myocardial uptake of marker on Positron Emission Tomography 
favouring a loss of myocardial sympathetic nerve terminals in patients 
with Parkinsonism  illness presenting with autonomic failure.101 
Hakusui et al (1994) & Orimo et al  (1999) found out a 
diminished MIBG uptake in most of the  Parkinsonism patients even in 
the early phase of  illness using meta 123 I Iodobenzyl guanidine 
myocardial scintigraphy which indicates cardiac sympathetic nerve 
disturbances.102 
 Samay Jain, Greg J et al (2011) studied autonomic dysfunction  
in pupillary and cardiovascular system in Parkinsonism. They evaluated  
spontaneous variations of diameter of pupil in darkness, constriction and 
reduction velocities and HRV and cardiovascular autonomic test in 35 
study subjects ( 17 Patients, 18 healty subjects ). The results of Pupillary 
unrest and orthostatic standing test were highly significant in PD patients 
and reduced  HRV was recorded in PD patients.103 
 Popsil  P,  Konecwy l  et  al  (2008) studied autonomic dysfunction 
and progression of Parkinson’s disease in 25 patients using power 
spectral  HRV  analysis  which is coupled with metronome controlled 
breathing in lying down position .They found out significantly reduced 
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LF(Power),HF(power),Total Power in Parkinson’s disease patients. They 
suggested  short  term  HRV  examination  is  also  sensitive  enough  to  
compare the autonomic dysfunction in various  stages of Parkinson’s 
disease .104 
 Devo’s D, Krumova M et al(2003)  studied correlation between 
HRV and severity of Parkinsonism in 30 patients. They found out 
reduced LF(power), HF(power),PNN50 in Parkinson’s disease 
patients.105 
 Turkka et al ( 1987) revealed  that  low  levels  of  serum  Nor  
epinephrine and its metabolite in Parkinsonism  patients in response to 
standing up.106   
 Nicolas Sauvageot,Michel, Valliant et al (2007) studied HRV in 
35 patients and 35 subjects and their result was reduced sympathetically 
induced HRV  and low LF/HF ratio during sleep in Parkinsonism  
patients and they added a note on Postganglionic noradrenergic 
cardioselective denervation in Parkinsonism. 
 T.szili-Toro K, L.Rudas, G.Dibo et al (1999) did HRV and 
cardiovascular autonomic reflex test in 20 Parkinson disease patients and 
18 healthy subjects. He divided the Parkinson’s disease patient into 
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normal baroreceptor sensitivity group and impaired baroreceptor 
sensitivity group. Average RR  interval length was shorter in Parkinson’s 
disease patients , RMSSD was significantly lower and much reduced 
TP,LF,HF in Parkinson’s disease patients. 107 
 T.H.Happaniemi, V.Pursiainen et al(2001) have performed HRV 
analysis of 24 hr ECG recording in 54 untreated Parkinson’s disease 
patients and 47 age matched  normal subjects. They found low values of 
SDNN,VLF,LF,HF in Parkinson’s disease patients.108 
 Santigo, Perez-Lioret, Maria Veronica et al (2013) suggested 
that orthostatic hypotension in Parkinson’s disease represent cardiac 
autonomic dysfunction and it  is predominantly of altered baroreflex 
activity resulting from cardiac and vascular sympathetic denervation .109 
 Shin-  Yuan  Chen,  Cheryl  C.H  Yang  et  al  (2010) did  a  
retrospective cohort study in 24 men, 4 women with advanced 
Parkinson’s  disease  patients  to  find  out  the  correlation   of  HRV  with  
clinical outcome in Parkinsonism  patients after subthalamic deep brain 
stimulation. Patients underwent Deep brain stimulation for 9-32 months, 
day time ECG for 5 minutes. They found  increase in LF power but not in 
HR,LF%,HF% after deep brain stimulation.110 
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 Appenzeller & Goss et al (1971), Turkka et al (1987,1997), 
Haapaniemi et al (2000)  revealed that Heart rate responses to Valasalva 
manoeuvre and deep breathing test is being reported as significantly 
diminished in patients with Parkinsonism.111 
 The BP response to isometric handgrip test is also reduced with 
reference to Gross et al (1972),Van Dijik et al (1993).117,118   Diminished 
spectral power values is being obtained from 24 hr ECG recordings 
according to Mastrocola et al (1999).118 
 Wang SJ ,Shan DE et al studied Symapthetic Skin 
Response(SSR) and R-R interval variation in  62 Parkinson’s disease 
patients and 62 age matched controls. They suggested that abnormal SSR 
in Parkinson’s disease patients is associated with the duration of illness 
and it may be due to intermediolateral coloumn dysfunction. The 
abnormal RRIV was not related to staging and duration of disease.119 
 Hirashima F, Yokota T et al (1996) evaluated  83 patients with 
Parkinson’s disease using Sympathetic Skin Response(SSR) and sweat 
response to acetyl choline injection. They found  significantly attenuated 
amplitude and abnormal SSR in Parkinson’s disease.  The sweat volume 
was low and diminished number of sweat glands had been revealed from  
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local sweat response to acetyl choline which reflects the dysfunction of 
postganglionic sympathetic fibre in Parkinson’s disease.120 
Thus, the above clinical  studies have observed differences with 
sympathetic nervous system and parasympathetic system activities in 
Parkinson’s disease. However differences in sample size, age of the 
subjects, stress conditions, stage of the disease and psychological 
parameters may explain the varied results by these studies.  
The current study proceeds with assessment of the autonomic 
functions using Heart Rate Variability at rest in Parkinson disease 
patients with no gender preferences. 
2.14.   INSULIN 
 It is a polypeptide hormone secreted by the beta cells of islets of 
langerhans of pancreas concerned with metabolism of carbohydrate, 
protein and fats. 
2.14.1.   STRUTURE & BIOSYNTHESIS 
 The human insulin consists of 2 straight peptide chains, A (having 
21 amino acid) and B (having 30 amino acid). These chains are 
connected to each other by two inter chain disulphide linkages A7 to B7 
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and A20 to B19. In addition there is an intra chain disulphide bridge 
between 6 and 11 amino acid of A chain. Molecular weight of human 
insulin is 6000 daltons. 
 The insulin gene is localised on chromosome 11 directs the 
production of pre-pro-insulin (108 amino acid, molecular weight 11,500 
dalton). Pre-pro-insulin is cleaved to form pro insulin having 86 amino 
acid and molecular weight 9000 daltons. As the pro-insulin containing 
the A & B chain of insulin and the connecting peptide is guided to Golgi 
apparatus, disulphide linkages are established to yield the folded pro-
insulin molecule. Pro-insulin is further cleaved in Golgi apparatus to 
form the active hormone insulin and a connecting peptide  
(C peptide).(Steiner DF et al2001)122 
2.14.2. MECHANISM OF INSULIN SECRETION 
 Blood glucose is the major stimulant of insulin secretion. Glucose 
diffuses into the beta cells  by binding with the GLUT2 receptors on the 
beta cell membrane. Inside the beta cells, glucose is oxidized to ATP by 
the enzyme Glucokinase which act as a fundamental glucose sensor. 
 Increased ATP levels results in closure of ATP sensitive  
K+ channels and suppresses the K+ efflux and suppresses the K+ efflux 
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causing depolarization of beta cells. Depolarization opens voltage 
regulated ca2+ channels leading to increase in intracellular Ca2+. Elevated 
Ca2+ concentration activates the mean for insulin secretion from the 
secretory granules by exocytosis. (Langin D et al 2001) 52 
2.14.3  REGULATION OF INSULIN SECRETION 
 Glucose, amino acids, free fatty acids, ketoacids, potassium control 
insulin secretion by a feedback mechanism. Gastrointestinal hormone 
increases insulin secretion. Growth hormone, cortisol, glucagon also 
stimulate insulin secretion. But, prolonged secretion of these hormones 
leads to burning out of the islets resulting in Diabetes mellitus. 
Sympathetic nerves and epinephrine inhibit insulin secretion. 
Parasympathetic nerves and acetylcholine stimulate insulin secretion. 
(Berne & Lewy) 52 
2.14.4. PLASMA LEVELS AND FATE OF INSULIN 
 Average peripheral plasma insulin level is 10 μu/ml. Insulin 
circulates unbound to any carrier protein. Half life of insulin in the 
plasma is 5 to 8 minutes. Insulinase, a protease enzyme in the kidney and 
liver degrades insulin. 
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2.14.5. INSULIN RECEPTOR 
 It is a protein kinase receptor which contains enzyme activity. 
About 2 to 3 lakh insulin receptors are present in the cell membrane of 
target tissue for insulin.(Kido Y et al 2001; Seinos,Seino M,Bella I 1990) 
123,124,125    Insulin receptor is a tetramer having 2 α subunits and 2 β 
subunits. One α subunit is bound with β subunit by a disulphide bond to 
form a dimer. Two such identical dimers are located on the outer surface 
of the plasma membrane and contain the insulin binding domain. Β 
subunit spans across the plasma membrane and reside largely within the 
cytoplasm. These have tyrosine kinase domain.  
 Down regulation of insulin receptors results in Insulin resistance. 
Among the insulin receptor isoforms, insulin receptor –A isoform is 
mainly seen in nerves and mediates neuological functions such as 
synaptic transmission, plasticity. The effects of Insulin receptor –B 
isoform are typically metabolic.(Belfiore A et al 2009) 125 
2.14.6.   MECHANISM OF INSULIN ACTION 
 The first and overall rate limiting step in insulin action is transport 
of insulin through the capillary wall to the target tissues such as muscle, 
adipose tissues. Once insulin arrives at the target cell, it binds with the α 
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subunit of insulin receptor.( Pederson TM et al 2001, Schwartz MW etal 
1992)126,127 Binding insulin the α subunit stimulates the tyrosine kinase 
activity of β chains.  
 The activated tyrosine kinase then autophosphorylates the β chains. 
The phosphorylated receptor then phosphorylates the tyrosine residues on 
Insulin Receptor Substrate .(Flakoll PJ et al 2000)128 Insulin Receptor 
Substrate phosphorylations are followed by various cascades of events: 
1. Gene expression in the nucleus of target cell leading to biological 
actions 
2. Translocation of glucose transporters to the plasma membrane 
results in insulin mediated glucose uptake. 
3. Activation /deactivation of numerous enzymes in glucose and Fatty 
acid metabolism. 
4. Promotes protein synthesis. 
2.14.7.    ACTIONS OF INSULIN 
 The insulin have  a master role in the metabolism of carbohydrates, 
lipids, proteins with its target for action as muscle, liver and adipose 
tissue. Insulin increase potassium, phosphate and magnesium uptake into 
skeletal muscle and potassium & Phosphate into the hepatic cells from 
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extra cellular fluid by increasing the membrane permeability. Anabolic 
action of insulin promotes normal growth and development. Insulin 
stimulates other growth factors like Insulin like growth factor I & II, 
Nerve growth factor, EGF and relaxin.(Berne & Lewy) 52 
 
Figure 3 : MECHANISM OF ACTION OF INSULIN  
2.14.8.   INSULIN AND BRAIN 
 It is believed that both neuron and pancreatic β islets have evolved 
from a common ancestral neuron that produced insulin since they share 
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some similarities. (Rulifson SK, SK Kim et al 2002)129  Insulin enters the 
central nervous system through the circumventricular areas without the 
blood brain barrier and by the action of a specific insulin receptor that 
transports insulin into brains with the blood brain barrier.(SC Woods, 
R.J.Seelay et al 2003)130 
 Secretion of Insulin from pancreatic β cells determines its 
concentration in the periphery. Endothelial facilitated transport across the 
blood brain barrier into Cerebrospinal fluid  influences the brain insulin 
levels. These are controlled  independently of  variations  of plasma 
insulin. (Havrankova et al 1979)136  
 Endothelial saturation is the main factor limiting the  Insulin 
translocation during acute hyper insulinemia. Chronic hyperinsulinemia 
results in receptor internalization. There is evidence from the research 
studies that high insulin in blood leads to hyper insulinemia in 
Cerebrospinal fluid.(Wallum BJ et al 1987)137  
 Insulin also plays a role as neuronal survival factor and protects 
against the toxic effect of AMPA, oxygen and glucose deprivation and to 
prevent neuronal apoptosis. Therefore, when these protective effects of 
insulin have been lost, there may be increased risk of 
neurodegeneration.(M.Schafer, S.L.Erdo et al 1992, J.G.Mielke & 
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T.W.Yu 2005)134, 135   The decline of insulin receptor mRNA within the 
substantia nigra compacta which is the site of neurodegeneration in 
Parkinson’s disease is being demonstrated without involving the insulin 
levels. (Craft & Watson 2004)17   
 Tau is a microtubule associated protein that is responsible for the 
stabilization of microtubules inside the axons. Tau influences an effective 
axoplasmic flow , neuronal connections and signal transmission. Insulin 
plays a pivotal role in regulating Tau function. Increased levels of insulin 
load leads to Tau phosphorylation and neuronal degeneration.(S.Freude, 
L.Plum et al 2005, M.Hong, V.M.Y.Lee et al 1997)  138,139  
2.14.9.    INSULIN RESISTANCE 
  It is the physiological state in which cells fail to respond to the 
normal actions of insulin. In this condition, body produces insulin, but the 
cells become resistant to insulin and unable to utilize it. This results in 
hyperglycemia which leads to production of insulin from β cells further 
contributing to hyperinsulinemia. 
 Insulin resistance may be due to mutation in insulin receptor or its 
kinase activity, down regulation of insulin receptor or alteration in the 
second messenger transduction.  
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2.14.10.   DIAGNOSIS 
1.  Fasting serum insulin levels more than upper limit of normal 
considered evidence for insulin resistance. 
2.  Glucose tolerance test is normal or mildly impaired in insulin 
resistance. 
3.  Hyper insulinemiic euglycemic clamp – this is the gold standard 
test for measuring and quantifying the insulin resistance. 
4.  Modified insulin suppression test – this is the alternative test to 
assess the insulin resistance developed by Corald Reaven at 
Stanford University. 
5.  HOMA –IR & QUICKI TEST. 
 Homeostatic Model Assessment of Insulin resistance and 
Quantitative Insulin sensitivity Check Index are the simplified tests to 
measure the Insulin Resistance. Both  fasting insulin and glucose levels 
are used to calculate the insulin resistance. (Matthews DR 1985)144 
2.14.10. INSULIN RESISTANCE & NEURODEGENERATION 
 Possible mechanisms explaining the role of insulin resistance in 
Neurodegeneration  are (Arthur F Schuh et al 2011)145 
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1. Sensitization of neurons to toxins and other insults in the presence 
of high insulin levels 
2. Decrease transportation of insulin into brain 
3. Tau phosphorylation caused by the brain insulin resistance 
4. Brain localized hypoglycemic states due to insulin resistance.  
2.14.11.   INSULIN RESISTANCE & PARKINSON’S DISEASE  
 Many clinical studies have demonstrated an association between 
Insulin Resistance and Parkinson disease since impaired  glucose 
tolerance has been documented  in > 50% of  parkinsonism patients. 
(Sandyk 1993) 146 
 Diminished insulin mediated uptake of glucose, inhibition of initial  
secretion of insulin and presence of chronic hyperinsulinemia and 
hyperglycemia after  loading the glucose have been reported in newly 
diagnosed untreated patients with Parkinsonism. (Von Woert & Muller 
1971; Boyd et al 1979)140,16 Levdopa used in the management of 
Parkinsonian illness produces both hyperglycemia and hyperinsulinemia. 
 The association between insulin resistance and Parkinson’s disease 
is best explained by the common pathophysiological pathway (i.e.) the 
GIGYF2 gene involved in signaling pathway now has been identified as 
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Park 11 gene. (Eva schern Hammer, Jonni Hansen et al 2011)142 The 
relationship between the insulin resistance and Parkinson’s disease and 
the impact of co-morbidity on their pathogenesis is not clear till 
now.(Morris JK 2010)39 
 Insulin receptors are abundantly present  in the dopaminergic nerve 
cells of substantia nigra Pars compacta (Unger et al 1991) 143 which is 
evident from the histopathological studies of patients with Parkinsonian 
illness. Insulin resistance leads to loss of insulin receptor mRNA which 
coincides with the loss of tyrosine hydrxylase mRNA.(Mooroo et al 
1999) 147  Tyrosine hydroxylase is the rate limiting enzyme in dopamine 
synthesis. Thus, insulin resistance affects the synthesis of dopamine in 
substantia nigra pars compacta. 
 In animal models, elevation of glucose concentration in blood leads 
to suppression of firing of dopaminergic nerve cells in the substantia 
nigra pars compacta.(Craft & Watson ,2004)17  It is found that there is a 
profound reduction of  metabolism of dopamine in nigrostriatal tract and 
olfactory tubercle on administration of glucose to rat.(Montefucso et al 
1983)148 
 Chronic hyperglycemia out of insulin resistance results in oxidative 
stress and produces reactive oxygen species.  Insulin resistance leads to 
57 
 
the synthesis of oxygen free radicals which  may result in the 
dopaminergic  nerve cell loss. The above discussed two scenarios 
including the loss of nigrostriatal dopaminergic nerve cells and 
development of insulin resistance are mediated by oxidative mechanisms. 
So, insulin resistance and neurodegeneration in Parkinson’s disease might 
be linked through oxidative stress. 
 Even though glucose uptake in neuronal cell is independent of 
Insulin, protein involved in insulin signaling such as IRS2 (Insulin 
Receptor substrate) & GLUT 4 are abundantly concentrated in basal 
ganglia. So, the altered insulin signaling may impair nigrostriatal 
dopamine.(Jill & Morris et al 2013) 39  The association between the 
insulin resistance and Parkinson’s disease highlighted the development of 
insulin sensitizing drugs such as thiozolidinediones and PPAR ү as novel 
and possible therapeutic agents for Parkinson’s disease. 
 A.E.Boyd, III. Harolde, Lebovitz et al (1979) evaluated 
disturbances in hormones activity and glucose metabolism in patients 
with Parkinsonism. They did plasma glucose, insulin and Growth 
hormone levels in response to oral glucose, IV glucose and IV insulin 
before and after L.dopa therapy. 44% of control group patient showed an 
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inhibition of initial secretion of insulin, hyperglycemias, hyper 
insulinemia after loading the glucose .16 
 
 
 
 
 
 
 
 
Figure 4 : SCHEMATIC OVERVIEW OF EMERGING PATHWAYS CONNECTING 
INSULIN RESISTANCE & NEURO DEGENERATION  
FFA - Free fatty Acid, HLA - Human leucocyte antigen, IL-6 – Interleukin 6, NO- Nitric oxide, UPS- ubiquitin proteosome 
system, SNCA- α synuclein, PGCI α -  PPAR γ receptor coactivator, LRRK2 – Leucine rich repeat kinase, 
 
 Ivan J lipman, Michael E, Boykin et al (1974) studied oral 
glucose tolerance test in unselected group of Parkinson’s patients. The 
higher values of blood sugar found in Parkinson’s patients  which was 
independent of  age, duration of  illness, severity of disability. Blood 
sugar values are more when compared to random population of similar 
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age. 52.4% of group of 63 consecutive Parkinson’s patients revealed 
impaired glucose intolerance. 
 Domenico  Bosco, Massimilliano plastino et al (2012) studied 
carbohydrate metabolism in 110 Parkinson’s disease patients with or 
without dementia. They evaluated the insulin resistance, glucose, insulin 
levels after 2 hour oral glucose tolerance test in 53 Parkinson’s disease 
patients with dementia and 57 Parkinson’s disease patients without 
dementia. The insulin resistance was  highly prevalent in 62% of 
Parkinsonism patients with dementia of which 30% had impaired glucose 
tolerance, 5.6% were newly diagnosed diabetes mellitus and 26% had 
only insulin resistance. The prevalence of insulin resistance in 
Parkinson’s  patients  with  dementia  was  found  to  be  twice  than  that  of  
Parkinson’s patients without dementia.74 
 Morris  JK,  Bornhoff  GL  et  al  (2010) studied the relationship 
between the neurodegeneration and insulin resistance in a preclinical 
animal model of Parkinson’s disease. High fat feeding is an established 
animal model of insulin resistance. Higher HOMA IR indices & 
diminished insulin mediated glucose uptake support the abnormal insulin 
sensitivity. Animals fed in the high fat diet group showed profound  
Dopamine secreting nerve loss in the Nigrostriatal pathway. Peripheral 
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insulin resistance would exaggerate the  toxin induced nigrostriatal 
dopaminergic neurodegeneration.39 
 M.H.Van woert, P.S.Muller et al (1973) studied on insulin 
secretion and glucose metabolism in Parkinson’s disease patients before 
and during treatment with L-dopa compared with age matched controls. 
The Parkinson’s disease patients showed that disappearance rate  of 
glucose was very less and a response of insulin to IV glucose was also 
very less which were not modified by treatment with L-dopa. Their 
findings support a  defective mechanism in the IV glucose mediated 
insulin release in Parkinson’s disease patients.140 
 Borrislav Ivanov, Ara Kaprelyan et al (2012) studied the link 
between the pathophysiological pathways of parkinsonian illness and 
Type 2 diabetes mellitus in 85 Parkinson disease patients. They found the 
prevalence of insulin resistance in Parkinsonism is 18.8%. They 
suggested that changes in glucose control was associated with loss of 
dopaminergic neurons which may occur in the early phase of disease.121 
 Gang Hu,Peek Jous J lahti et al (2007) prospectively studied the 
51,552 men and women in 25-74 years of age without history of 
Parkinson’s disease at baseline. During the course of 18 years, 324 men 
and 309 women with impaired glucose tolerance developed incident 
Parkinson’s disease. 
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 F  Federico,  IL  Simone  et  al  (1997) performed Proton Magnetic 
resonance spectroscopy in 8 patients with Parkinson’s disease which 
revealed abnormal glucose utilization and striatal neuronal loss in 
Parkinson disease.141 
 Sandyk (1993) studied the impact of chronic hyperglycemia, 
abnormal glucose intolerance on the severity of disease and the course of 
illness  as  it  has  been  documented  that  50  %  to  80%  of  Patients  with  
Parkinson’s disease revealed impaired  glucose tolerance. Insulin 
resistance might exacerbate the severity of illness in Parkinson’s disease 
and levodopa induced dyskinesias. He suggested that Parkinson’s disease 
patients should be routinely examined for the evidence of glucose 
intolerance and that if found aggressive management of the insulin 
resistance and hyperglycemia diminish the severity of the disease.146 
 From the above studies it is inferred that the prevalence of Insulin 
resistance is higher in patients with Parkinson’s disease due to many 
reasons. When it is associated with Parkinson’s disease it may increase 
the severity of the illness due to accentuated neurodegeneration and it 
throws light into the development of novel threpeutic agents for 
Parkinson’s disease. 
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3. AIM & OBJECTIVES 
AIM 
 To evaluate the Resting Heart Rate Variability and serum Insulin 
levels in patients with Parkinson’s disease. 
OBJECTIVES: 
1. To evaluate the resting cardiac autonomic activity in patients 
with Parkinson’s disease using Heart Rate Variability at rest 
and to be compared with the healthy subjects. 
2. To study the prevalence of Insulin resistance in Parkinson’s 
disease patients by evaluating serum insulin levels. 
3. To correlate Insulin resistance with Heart Rate Variability 
variables in Parkinson’s disease patients. 
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4. MATERIALS AND METHODS 
The study was conducted in the Institute of Physiology and 
Experimental Medicine, Madras Medical College and Rajiv Gandhi 
Government General Hospital, Chennai-3, after getting permission  
from the Institutional Ethical Committee, Madras Medical College, 
Chennai – 3. 
4.1.  PATIENT SELECTION  
 Patients of both sexes in the age group between 40 – 70 years 
fulfilling the criteria for Parkinson’s disease as per the Parkinson’s 
disease Society Brain Bank Clinical Criteria were included in the study. 
Hoehn  and  Yahr  scale  was  used  to  assess  the  severity  of  motor  
impairment in this study.  
 They were selected from the Institute of Neurology, Rajiv Gandhi 
General Hospital, Chennai - 3. All the Participants included were 
informed about the study and a written and informed consent were 
obtained from them.  
 Detailed history including symptoms of autonomic dysfunction 
such as giddiness on standing / near syncope, palpitation, symptoms of 
bladder disturbances such as retention, hesitancy, urgency, incontinence 
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of urine, features of bowel disturbances such as constipation, diarrhoea, 
loss of libido were elicited. All the participants were subjected to 
complete general and systemic examination. 
4.2.  INCLUSION CRITERIA 
30 Patients with Parkinson’s disease of the age group between  
40 – 70 years were included in the study. 
4.3.  EXCLUSION CRITERIA 
· Patients with atypical Parkinsonism, Parkinson plus 
syndrome, Multisystem atrophy, Supra nuclear palsy 
· Patients with Secondary Parkinsonism (vascular, traumatic, 
drug induced) 
· Patient with diabetic autonomic neuropathy 
· Patent taking medication that may act directly on ANS 
(calcium channel blocker, sedative etc) 
· Patient with cardiovascular diseases 
· Patient with impaired hepatic, renal function 
· Patient with severe mental illness 
· Patient with concomitant neurological & musculoskeletal 
disorder 
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4.4.  SELECTION OF CONTROLS 
The Control group consisted of 30 healthy subjects (men, women) 
with the age between 40-70 years were included in the study after history 
taking, clinical examination and laboratory tests. 
4.5.  LABORATORY ASSESSMENT 
Laboratory investigations include Haemoglobin, Fasting blood 
sugar, postprandial blood sugar, blood urea, serum creatinine. Insulin 
resistance is studied by Fasting serum insulin and Fasting blood sugar. 
4.6.  MATERIALS 
· Niviqure ambulatory digital ECG recorder (INCO) 
· Pulse rate and NIBP recorder – PLANET -50 
· Sphygmomanometer 
4.7.  EQUIPMENT 
Niviqure is a solid state, multi load, digital, stand alone 
computerized recording system designed to acquire, analyze and store 
ECG data over long hours. This data is acquired and stored in flash 
memory for later downloading and analysis. The data transfer from 
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memory module and computer is through an interface RS233C, 
compatible module.   
Niviqure has powerful processing software for online ECG study, 
data storage, off line data replay and study and data transfer to other 
software for statistical analysis and FFT analysis. Flow chart given below 
summarizes the individual steps for obtaining the information for HRV 
analysis. 
 
 
 
 
 
 
4.8.  MEASUREMENT OF HEART RATE VARIABIITY 
 HRV analysis gives a non-invasive estimate of the function of 
sympathetic and Parasympathetic nervous system of heart. Either the 
heart rate as a function of time or the period of time between successive 
QRS complexes needs to be quantified in HRV analysis. 
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4.9.  HRV ASSESSMENT 
 Two types of recording are commonly used for the standardisation 
of electrophysiological and clinical studies, two types of recording are 
commonly used (Task Force)66 
a. Short term recording (5 min) – computed by frequency domain 
methods. 
b. Long term recording (24 hour) - computed by time domain 
methods. 
 HRV can  be  assessed  either  for  a  short  term (5  minutes)  or  for  a  
long term (24 hours). Frequency domain methods are more preferable for 
short term recording and time domain methods are preferred for long 
term recording. (Task Force,1996)66 
 A good quality of ECG recordings without artefact RR interval 
tachogram consisting of only normal to normal of RR interval resulting 
from sinus node depolarization is taken for HRV analysis. HRV is 
analyzed using the Finland software IV of version 1.1, Microsoft window 
based PC that gives the report sheet with time domain and frequency 
domain variables for various events which are already marked in the 
ECG. 
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4.9.1.   TIME DOMAIN METHODS 
 The simplest that can be  calculated directly from the raw RR 
interval time series are the time domain methods. The mean HR and 
mean RR and standard deviation of the RR intervals are the simplest time 
domain measures. 
 The simplest time domain measures are  
 Mean HR – mean of the selected RR interval 
 Mean RR- mean of the selected RR series. 
 The overall variation in the RR interval signal is best described by 
SDNN  that  is  standard  deviation  of  NN  intervals.  The  short  term  
variation are best described by standard deviation of consecutive 
differences between consecutive RR intervals (SDSD). NN50 is the  
other commonly used parameter which is calculated from the  number of 
consecutive RR intervals differing more than 50 ms.  
 The percentage value of NN50 intervals is pNN50. The normal-to-
normal intervals (i.e. intervals between consecutive QRS complexes 
resulting from sinus node depolarization) is given by the prefix NN. In 
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practice, RR and NN intervals usually share the same meaning. 
(Task Force,1996)66 
4.9.2. STATISTICAL METHODS 
 The more complex statistical time domain measures could be 
calculated from a series of instantaneous heart rate or cycle length 
intervals which are recorded over longer period, usually for 24 hours,. 
These can be divided into (i) those calculated from direct measurement of 
NN intervals or instantaneous heart rate and (ii) those computed from the 
difference between NN intervals.  
 The  SDNN  is  the  standard  deviation  of  these  Normal  to  Normal  
intervals which represents the  total power of spectral analysis. This is the 
simplest variable to be calculated using statistical methods. Unit of 
SDNN is given in milliseconds. SDNN act as a universal index of HRV. 
All the long term components and circadian rhythm which is causative 
for the variability in the recording period is best represented by SDNN. 
(Saul JP, Albrecht P et al 1993)97 
 The  standard  deviation  of  the  averages  of  NN  intervals  in  all  5  
minute  segment  of  the  full  recording  gives  SDANN.   The  variations  of  
the average of NN intervals in  5 minute intervals over 24 hours is given 
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by SDANN. Thus, it gives information  on long term components and it 
is a more valuable indicator of low frequencies like physical activity, 
changes in state of body and circadian rhythm.  Another most reliable 
index is pNN50 that measures what percent of the inter beat intervals 
differ from the neighboring intervals by 50 milliseconds or more and it is 
expressed in percentage.(Task Force,1996)66 
 SD or SDSD represents the standard deviation of differences 
between adjacent NN intervals. RMSSD is another variable calculated 
from the square root of the mean of the sum of the squares of difference 
between adjacent NN intervals. It corresponds to high frequency variation 
in short term NN recordings which gives an estimate of vagal modulation 
of the heart.  Unit of RMSSD is milliseconds. (Task Force,1996 )66 
4.9.3.  FREQUENCY DOMAIN VARIABLES 
 The fundamental information regarding the distribution of the 
power (variance) as a function of frequency is best given by  Power 
spectral density (PSD) analyzer  in frequency domain, in spite of various 
spectral methods for studying R-R tachogram. With the use of proper 
mathematical algorithms, an estimate of true power spectral density can 
be obtained. They can be divided into 
71 
 
Non parametric methods (Fast Fourier Transform) 
Parametric methods (Auto regressive Models, Marple1987) 93 
 The  method of decomposition of periodic oscillations of heart rate 
signal at different frequencies and amplitude is best given by frequency 
domain analysis and gives valuable information on their relative intensity 
(termed variance or power) in the  sinus rhythm of heart. Frequency 
domain methods are more preferred when compared to the time domain 
methods  especially  with  the  analysis  of  short  term  recordings.  
(Task Force, 1996 )66 
 The Power Spectral Density (PSD) analysis is done by computing 
the powers and frequencies for various frequency bands. The commonly 
used frequency bands are as follows: very low frequency (VLF, 0-0.04 
Hz, low frequency (LF, 0.04-0.15 Hz), and high frequency (HF, 0.15-o.4 
Hz).(Sayers BM 1973; Hirsh JA, Bishop B et al 1981) 88 
Parameter Definition Frequency Range 
Total power Variance of NN intervals <0.4 Hz 
ULF Ultra low frequency <0.003 Hz 
VLF Very low frequency 0.0 – 0.04  Hz 
LF Low frequency 0.04 – 0.15 Hz 
HF High frequency 0.15 – 0.4 Hz 
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ULF: Includes the circadian rhythm. 
VLF: Supposed to be influenced by temperature regulation and 
humoral systems. 
LF: Affected by changes in cardiac sympathetic (and presumably 
Parasympathetic) activity. 
HF: Sensitive to changes in respiratory rhythm and primarily 
influenced by cardiac parasympathetic activity.   
 The usual parameters to be analyzed in frequency domain are 
found to be the powers of VLF, LF, and HF bands in absolute and 
relative values, and the normalized power of LF and HF bands, and the 
LF / HF ratio. For each frequency band, the peak frequencies are 
calculated too.  By integrating the spectrum over the frequency bands, 
spectrum powers are given for the Fast Fourier Transformer (FFT).(Task 
Force,1996) 66 
 A continuous smooth spectrum of activity is observed in the 
parametric method (Autoregressive model) results which  is more 
complex and has to be verified with the suitability of chosen model.(Task 
Force,1996)  66 
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4.10.    SPECTRAL COMPONENTS 
SHORT TERM RECORDING 
  In this study we have performed only short time HRV recording 
that for 5 minutes. In non parametric method, Fast Fourier Transform 
(FFT)  is  used  as  algorithm.  This  is  very  simple  and  rapid.  It  has  a  high  
processing speed. The Power Spectral Component has recordings ranging 
from 4-400 MHz. (Sayers BM 1973; Askerold et al 1981; Pagani 
M,Lombardi F et al 1986)85,88,99 
 The three main components that are distinguished in a spectral 
calculation for short term ECG recording are 
   VERY LOW FREQUENCY (VLF) 
   LOW FREQUENCY (LF) 
   HIGH FREQUENCY (HF)  
There  is  no  constant   distribution  of  the  power  and  central  
frequency of LF and HF but they may vary in relation to changes  in the 
sympathetic and parasympathetic modulation of the heart.  The most 
commonly accepted component of VLF is believed to be the non 
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harmonic component with no coherent properties which is influenced by 
algorthim of baseline or trend removal.  
 LF and HF can be calculated  in normalized unit. The measurement 
of LF and HF in normalized unit best explains the coordinated and 
balanced behavior of Autonomic Nervous system. Normalized unit 
means the relative value of each  LF, HF power component in proportion 
to  the  total  power  minus  the  VLF  component  (TP-VLF).(Task  
Force1996)66 
 HF component is believed to be a quantitative a marker of 
parasympathetic (vagal) modulation. This HF component is mainly 
mediated  by respiratory movements and it is influenced  by the 
frequency of breathing. The LF component is influenced by both 
sympathetic and vagal modulation. LF/HF ratio is a strong indicator of 
sympatho-vagal balance.    
4.10.1 . VERY LOW FREQUENCY VLF (0-0.04Hz) 
 There is much less defined   physiological basis for the VLF 
component and the existence of a specific physiological process 
influencing these VLF component might even be questioned. Thus VLF 
computed  from short-term  HRV analysis(e.g. 5 min) is a dubious 
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measure  and  should  be  avoided  while  analyzing   the  PSD of  short-term 
ECGs. Therefore, in the present study only LF and HF was studied. 
(Malliani et al 1991)96 
 4.10.2.  LOW FREQUENCY LF (0.04-0.15Hz)s 
           This is an important indicator for more sympathetic than 
parasympathetic modulation. This requires a minimum of 2 minutes 
recording. 
4.10.3.  HIGH FREQUENCY HF (0.15-0.4Hz) 
  This power spectral oscillation is mainly seen only for 
parasympathetic   nervous system. Hence, this is specially blocked by 
parasympatholytic drugs. It can be calculated even with 1 minute ECG 
recording. 
4.10.4.  LOW FREQUENCY/HIGH FREQUENCY RATIO: (LF/HF 
RATIO) 
 LF/HF ratio has been used as a better non – invasive index of  
global sympathovagal balance. Interpretations of these HRV indices 
mainly rely upon the existing physiological state. (Pagani M et al 1986) 95 
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4.10.5. NORMALIZATION OF UNITS 
 LF (n.u) and HF (n.u) are the normalization of the powers that 
gives near 100% values of the sympathetic and parasympathetic system. 
They can be calculated as follows (Task force, 1996) 
LF (n.u) = LF power / (LF + HF power) or LF power/ (TP –VLF) 
HF (n.u) =HF power/ (LF+HF power) or HF power/ (TP-VLF) 
Total power = LF power + HF power 
4.11.  METHODOLOGY 
 The sixty age and sex matched study and control group were 
subjected to assess resting heart rate variability using Niviqure 
ambulatory digital ECG recorder. 
Many endogenous and environmental factors can confound the 
autonomic testing and need to be controlled. The following precautions 
were taken while recording the Heart rate Variability. 
· The subjects should be calm, comfortable, mentally relaxed and 
free from recent acute illness, and without significant anxiety.  
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· The Heart rate variability was recorded between 10 -12 AM, 2 – 
3hours hours after breakfast. 
· Subjects were asked to remove any Compressive garments. 
·  Caffeine, nicotine and alcohol were avoided on the day of 
recording Heart rate variability. 
· Vigorous exercise was avoided on the day prior to the test. 
· Any other medication that could modulate the blood pressure was 
discontinued ideally 24-48 hours prior to recording. 
· The subjects were asked to empty the bladder before the test. 
· The test was performed in quiet room with controlled temperature 
ranging from 25-28 degree Celsius lighting subdued.  
· All mobile phones, electronic items weres kept 1 metre away from 
the recording site  
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Photograph 1- Niviqure ambulatory digital ECG recorder 
4.12.  RESTING HRV RECORDING 
· After explaining briefly about the study, the informed consent  
from the subjects are obtained. 
· Height in meters and weight in kilograms were measured and 
their BMI were calculated. 
· Patients were instructed to lie down in supine posture and relax 
for a period of 10- 15 minutes.  
· Resting heart rate and blood pressure were recorded. 
· Electrodes were placed in the position as given below after 
cleaning the site with spirit. 
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PLACEMENT OF ELECTRODES 
ELECTRODE POSITION 
Exploring electrode Lt Shoulder 
Exploring electrode Rt Shoulder 
Exploring electrode Lt subcostal 
Reference electrode Rt Subcostal 
 
·  Resting HRV was recorded in the supine position using ECG 
recorder. 
·  It was recorded for 320 seconds which is needed for short term 
HRV analysis. 
 
 
 
 
 
Photograph 2- Resting HRV analysis recording 
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· After screening for the artifacts and editing it, the results 
obtained were fed to the HRV analysis software. 
· The  analogue  to  the  digital  conversion  of  the  resting  ECG  
signals was done by a AD converter with a sampling frequency 
of 1024/ sec. 
· The Power spectral analysis of the converted ECG signals was 
done by using Fast Fourier Transformation  
4.13.  PARAMETERS STUDIED 
Mean RR, Mean HR, SDNN, RMSSD, NN50, pNN50,  LF power, 
HF power, LF/HF ratio, Total Power were estimated. The values are 
Compared with the normal values obtained from the control group. The 
results of these tests are evaluated statistically. 
4.14. ASSESSMENT OF SERUM INSULIN LEVELS 
· Under aseptic precautions about 5ml of blood was collected from 
the patient and controls after 10 hours of fasting. 
· The blood was centrifuged to separate the serum. 
· The serum samples were stored at -20 degree Celsius. 
· ACCUBIND Elisa microwells Insulin Test system was used for 
assessing the serum Insulin levels. 
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4.15.  MATERIALS REQUIRED 
  1. Insulin calibrators – six vials of references for Insulin antigen at 
levels of 0,5,25,50,100,300 μ IU / ml 
 
 
 
 
 
Photograph 3- Insulin kit 
 
 
 
 
 
 
Photograph 4 –ELISA reader at TNMGR University 
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2.  Insulin enzyme reagent – containing enzyme labelled affinity 
purified monoclonal mouse x-insulin IgG, biotinylated monoclonal 
mouse insulin IgG in buffer 
3.  Streptavidin coated plate – 96 wells 
4.  Wash solution concentrate 
5.  Substrate A & Substrate B 
6.  Stop solution 
4.16.   INSULIN ASSAY PROCEDURE 
Ø Wash buffer solution and working substrate solution were 
prepared. 
Ø 50 μl of the appropriate calibrators, controls and samples were 
pipetted  into the assigned wells. 
Ø 100 μl of the Insulin Enzyme Reagent was added to each well. 
Ø The microplate was gently swirled for 20 -30 seconds for proper 
mixing. 
Ø The microplate was incubated for 120 minutes at room 
temperature. 
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Ø The contents of microplate were discarded either by decantation 
or aspiration. 
Ø 350 μl of wash buffer was added and then decantated or aspirated. 
Ø Three washes were repeated using automatic or manual plate 
washer. 
Ø 100 μl of working substrate solution was added to all wells and 
mixed gently for 15-20 seconds. 
Ø The absorbance was read in each well at 450 nm in a microplate 
reader.  
4.17.  CALCULATION OF RESULTS 
A dose response curve was used to determine the concentration of 
Insulin. 
 1.The absorbance for each duplicate serum reference and the 
corresponding Insulin concentration in μl/ml were plotted on a graph 
paper. 
 2. The best fit curve was selected from the plotted points. 
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 3. The average absorbance of the duplicates for each unknown 
solution was plotted on Y axis, the corresponding insulin concentration is 
obtained from the X axis. The normal value of serum insulin in adult is 
0.7 – 9 μIU /ml. 
4.18. HOMA-IR (HOMEOSTATIC MODEL ASSESSMENT-
INSULIN RESISTANCE) 
The Homeostatic Model Assessment is a new method used to 
quantify insulin resistance which was first described by Matthews et al in 
1985. It was derived from the data of the various physiological studies 
using the mathematical equation to describe the glucose regulation. 
HOMA-IR= Glucose X Insulin 
405 
(Glucose in mass units mg/dl), IR – Insulin resistance, Blood for 
insulin and glucose are taken during fasting. HOMA-IR > 2 – 2.5 
considered as significant for insulin resistance in non-diabetic population. 
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5. RESULTS 
The statistical analysis of the data obtained from conducting the 
Heart Rate Variability test and serum insulin levels were done using the 
statistical Package for the social sciences (SPSS) software version 17. 
The mean and standard deviation of the variables were determined for 
both  the  groups.  Independent  student  t  test  was  employed  as  the  test  of  
significance at 95% confidence interval. P value <0.05 was considered as 
significant. 
5.1. CHARACTERISTICS OF CONTROL & STUDY 
POPULATION 
 The characteristics of control and study population are furnished in 
the table-1. Table(1)a comprises the age distribution between the control 
and cases. 
TABLE I (a) – AGE 
VARIABLE GROUP MEAN±SD T TEST P VALUE 
   AGE Control 55.9 ± 6.18  
0.7236 
 
0.472 
Cases 57 ± 5.58 
 P < 0.05 Significant 
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 Among the individuals screened, the mean age of the subjects was 
found to be 55.9 ± 6.18 years with the age range of 40 to 70 years in the 
control; whereas the mean age of the Parkinson’s disease patients 
included in the study was 57 ± 5.58 years. The difference in the age 
among the group was not significant. 
Table I (b) comprises the gender distribution between the cases and 
controls. 
Table 1(b) - GENDER 
GROUP  MALE FEMALE TOTAL 
 
Controls 
n 18 12 30 
% 60 40 100% 
 
Cases 
n 20 10 30 
% 66.7 33.3 100% 
 
Total 
n 38 22 60 
% 63.3 36.7 100% 
 
87 
 
Among the 30 Parkinson disease Patients, 20 (66.7%) were males and the 
remaining 10 (33.3% ) were females. Similarly, of the 30 control 
subjects, 18 (60%  )were males and 12 ( 40%  ) were females. Hence, in 
this study, distribution of individuals both in the control as well as in the 
Parkinson’s disease group was almost equal and uniform according to 
gender. 
Table 1(c) shows the comparison of BMI between the cases and 
controls 
TABLE 1(C) – BMI 
VARIABLE GROUP N MEAN±SD T TEST 
P 
VALUE 
BMI Controls 30 22.08 ± 1.68 
1.777 0.08 
Cases 30 21.3 ± 1.71 
 P < 0.05 Significant 
The body mass indices were estimated as 21.3 ± 1.71 and 22.08 ± 
1.68 for control and parkinson’s disease patients respectively and the 
difference was not statistically significant. 
Graph 1 COMPARISON OF AGE AMONG THE STUDY GROUPS 
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The duration of illness of the Parkinson’s disease patients selected 
were from as low as 1 year to as high as 16 year which averaged 6 ± 4.6 
years. 
Table 2 (a),(b) compares the resting Heart rate, systolic blood 
pressure & diastolic blood pressure of the cases and controls. 
TABLE 2(a) – RESTING HR 
VARIABLE GROUP N MEAN ± SD T TEST P VALUE 
Resting HR Controls 30 78.03 ± 5.91 
1.858 0.06 
Cases 30 74.9 ± 7.10 
P value < 0.05 significant 
TABLE 2 (b) – RESTING SBP, DBP 
VARIABLE GROUP N MEAN ± SD T 
TEST 
P 
VALUE 
 
SBP 
Controls 30 120.86 ± 4.5 
3.306 0.001* 
Cases 30 113.06 ± 12.11 
 
DBP 
Controls 30 76.4 ± 4.99 
1.863 0.067 
Cases 30 73.53 ± 6.80 
*P value < 0.05 significant 
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The mean value of the resting HR and the mean value of the DBP 
between the cases and controls did not differ significantly. However, 
there was highly significant fall in the mean SBP in the Parkinson’s 
disease patients group. 
5.2.  RESTING HRV 
 Both  the  groups  were  subjected  to  the  analysis  of  HRV  by  
continuously recording the ECG in a relaxed supine position for 5 
minutes. Variables pertaining to Heart Rate Variability at rest in time and 
frequency domain between the normal subjects and Parkinson’s disease 
patients are furnished in the table 3 to table 9. 
Table 3- comparison of Mean HR & mean RR among the study 
groups 
TABLE -3 MEAN HR, MEAN RR 
VARIABLE GROUP N MEAN ± SD 
T 
TEST 
P 
VALUE 
 
Mean HR 
Controls 30 74.43 ± 5.04  
1.358 
 
0.1794 Cases 30 72.33 ± 10.25 
 
Mean RR 
Controls 30 0.809 ± 0.06  
1.967 
 
0.054 Cases 30 0.853 ± 0.11 
P value < 0.05 significant 
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The mean HR of the control was 74.43 ± 5.04 and the Parkinson’s 
disease group was 72.33 ± 10.25. The mean RR of the control group was 
0.809 ± 0.06 and that of Parkinson’s disease group was 0.853 ± 0.11. 
Both the values are not statistically significant. 
TABLE 4 – COMPARISON OF SDNN AMONG THE STUDY 
GROUPS 
TABLE 4 - SDNN 
VARIABLE GROUP N MEAN ± SD T TEST P VALUE 
 
SDNN 
Controls 30 70.75 ± 38.59 
2.198 0.03* 
Cases 30 52.06 ± 26.16 
    P value < 0.05 significant 
The  mean  value  of  the  SDNN  in  the  control  group  was  70.75  ±  
38.59 which differ significantly with the mean value of 52.06 ± 26.16 of 
the Parkinson’s disease patients. 
  
Graph 3 COMPARISON OF RESTING BLOOD PRESSURE 
AMONG THE STUDY GROUPS 
 
Graph 4 COMPARISON OF SDNN & RMSSD AMONG THE 
STUDY GROUPS 
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TABLE – 5 COMPARISON OF pNN50 & RMSSD AMONG THE 
STUDY GROUPS 
TABLE-5 pNN50, RMSSD 
VARIABLE GROUP N MEAN ± SD T TEST  P VALUE 
 
pNN50 
Controls 30 23.56 ± 12.62  
1.358 
 
0.179 Cases 30 18.12 ± 17.93 
 
RMSSD 
Controls 30 44.83 ± 22.89  
2.167 
 
0.03* Cases 30 34.05 ± 14.77 
               *P value < 0.05 significant 
The mean value of the pNN50 in the control group was 23.56 ± 12.62 and 
the mean value of the pNN50 in the Parkinson’s disease group was 
18.12± 17.93 which was not statistically significant.  
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TABLE  -6  COMPARISON  OF  LF  (ms2) AMONG THE STUDY 
GROUPS 
TABLE- 6 LF (ms2) 
VARIABLE GROUP N MEAN±SD T TEST 
P 
VALUE 
 
LF (ms2) 
Controls 30 171.03± 97.60 
3.382 0.001** 
Cases 30 101.7 ± 58.44 
** P value < 0.001 highly significant 
The LF power values which is an indicator of sympathetic tone 
was lower in Parkinson’s disease group and was highly significant. 
TABLE -7 COMPARISON OF HF (ms2) AMONG THE STUDY 
GROUPS 
TABLE- 7 HF (ms2) 
VARIABLE GROUP N MEAN±SD 
T 
TEST 
P 
VALUE 
 
HF (ms2) 
Controls 30 266.13 ± 170.74  
2.424 
 
0.01* 
Cases 30 179.7 ± 94.7 
* P value < 0.05  significant 
The HF power values which is an indicator of vagal tone was lower 
in Parkinson’s disease group and was highly significant. 
Graph 5 COMPARISON OF LF(ms2) , HF(ms2) & TOTAL POWER 
 
Graph 6 COMPARISON OF LF/HF RATIO AMONG THE STUDY 
GROUPS 
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TABLE -8 COMPARISON OF LF/HF RATIO AMONG THE 
STUDY GROUPS 
TABLE - 8  LF / HF RATIO 
VARIABLE GROUP N MEAN±SD T TEST 
P 
VALUE 
 
LF/HFratio 
Controls 30 0.719 ± 0.26  
2.451 
 
0.01 Cases 30 0.584 ± 0.153 
* P value < 0.05 significant 
The LF/HF ratio which is a global index of sympathovagal balance 
was significantly lower in Parkinson’s disease group. 
TABLE -9 COMPARISON OF TOTAL POWER AMONG THE 
STUDY GROUPS 
TABLE- 9 TOTAL POWER 
VARIABLE GROUP N MEAN±SD T TEST 
P 
VALUE 
TOTAL 
POWER 
Controls 30 482.3 ± 267.5  
3.009 
 
0.003* Cases 30 312.5 ± 154.8 
* P value < 0.05  significant 
The Significantly reduced total power values indicate the reduced 
HRV in the Parkinson’s disease group. 
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TABLE – 10 COMPARISONS OF FBS & FASTING SERUM 
INSULIN LEVELS AMONG THE STUDY GROUPS 
TABLE-10 FBS, FASTING SERUM INSULIN 
VARIABLE GROUP N MEAN ± SD T TEST P VALUE 
 
FBS 
Controls 30 97.3 ± 16.02  
1.732 
 
0.08 Cases 30 103.5 ± 11.3 
 SERUM 
INSULIN 
Controls 30 7.49 ± 3.22  
2.010 
 
0.04* Cases 30 9.22 ± 3.48 
*P value < 0.05 significant 
There was no significant difference in the fasting blood sugar 
among both the study groups. Serum insulin levels were significantly 
more in Parkinsonian illness patients than the control groups.  
  
Graph 7 COMPARISON OF FASTING  SERUM INSULIN 
LEVELS AMONG THE STUDY GROUPS 
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TABLE-11 COMPARISON OF HOMA- IR VALUES AMONG THE 
STUDY GROUPS 
TABLE-11 HOMA – IR (INSULIN RESISTANCE INDEX) 
VARIABLE GROUP N MEAN±SD T TEST P 
VALUE 
 
HOMA - IR 
Controls 30 1.71 ± 0.61  
3.569 
 
0.0007** Cases 30 2.32 ± 0.71 
*P value < 0.05 significant 
There was a highly significant difference in the P value < 0.001 in 
the HOMA-IR values between the study groups. HOMA-IR values are 
significantly high in Parkinson’s disease patients. 
5.3.  CORRELATION BETWEEN HRV PARAMETERS, HOMA-
IR VALUES ,FASTING INSULIN AND DURATION OF 
PARKINSON’S DISEASE 
The tables 12 to 17 show the correlation between duration of 
Parkinson’s disease, Heart rate variability parameters, Fasting insulin & 
HOMA-IR values. The correlation coefficients observed between the 
duration of Parkinson’s disease & HRV parameters were negative and 
two of them  were statistically significant. The correlation coefficients 
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observed between the HRV parameters and HOMA – IR values were all 
negative but none of them were statistically significant. 
TABLE 12-CORRELATION BETWEEN DURATION OF 
PARKINSON’S DISEASE AND LF (ms2) 
 Correlation coefficient 
and  p value 
Interpretation 
Correlation between 
duration of 
Parkinson’s disease 
and LF (ms2) 
 
r=-0.7519 
p=<0.0001*** 
 
Strong negative 
correlation and 
significant 
*P value < 0.05 significant 
TABLE 13-CORRELATION BETWEEN DURATION OF 
PARKINSON’S DISEASE AND HF (ms2) 
 Correlation coefficient 
and p value 
Interpretation 
Correlation between 
duration of 
Parkinson’s disease 
and HF (ms2) 
 
r=-0.7532 
p=<0.00001*** 
Strong negative 
correlation and 
significant 
*P value < 0.05 significant 
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TABLE 14- CORRELATION BETWEEN DURATION OF 
PARKINSON’S DISEASE AND LF/HF RATIO 
 Correlation coefficient 
and p value 
Interpretation 
Correlation between 
duration of 
Parkinson’s disease 
and LF/HF ratio 
r=-0.0156 
p=0.937 
weak negative 
correlation and not 
significant 
P value < 0.05 significant 
TABLE 15- CORRELATION BETWEEN HOMA – IR ,FASTING 
INSULIN AND LF (ms2) 
 Correlation coefficient 
and p value 
Interpretation 
Correlation between 
HOMA-IR and LF (ms2) 
r= -0.2718 
p=0.14 
Weak negative 
correlation and not 
significant 
Correlation between 
Fasting insulin & LF 
(ms2) 
r= -0.2387 
p = 0.20 
Weak negative 
correlation and not 
significant 
P value < 0.05 significant 
98 
 
TABLE 16- CORRELATION BETWEEN HOMA IR –  FASTING 
INSULIN AND HF (ms2) 
 Correlation 
coefficient and p 
value 
Interpretation 
Correlation between 
HOMA-IR and HF (ms2) 
r= -0.1773 
p=0.34 
Weak negative 
correlation and not 
significant 
Correlation between 
Fasting insulin & HF 
(ms2) 
r= -0.1792 
p = 0.34 
Weak negative 
correlation and not 
significant 
P value < 0.05 significant 
TABLE 17- CORRELATION BETWEEN HOMA IR ,FASTING 
INSULIN AND LF/HF RATIO 
 Correlation 
coefficient and p 
value 
Interpretation 
Correlation between 
HOMA-IR and LF/HF 
ratio 
     r= -0.2078 
p=0.27 
Weak negative 
correlation and not 
significant 
Correlation between 
Fasting insulin & LF/HF 
ratio  
r= -0.1544 
p = 0.41 
Weak negative 
correlation and not 
significant 
P value < 0.05 significant 
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5.4. SEVERITY OF PARKINSON’S DISEASE WITH HRV 
VARIABLES 
The Heohn and Yahr scale is used in this study to assess the 
severity of disease. Based on Hahn and Yahr scale, patients are divided  
into  three  groups  Group  I  (H&Y scale  1& 2),  Group  II  (H&Y scale  3),  
Group  III  (H&Y  scale  4,5).   Analyses  of  variance  for  the  effect  of  
severity of disease on HRV parameters were worked out and the results 
were furnished in the tables 18 to 20. Highly significant difference was 
found among Group I (H&Y scale 1&2). Group II (H&Y scale 3) , Group 
III (H&Y scale 4, 5) with respect to LF (ms2), HF (ms2). The LF/HF ratio 
was not found to be different among three groups of severity of disease as 
per ANOVA. 
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TABLE 18 ANALYSIS OF VARIANCE FOR THE SEVERITY OF 
DISEASE ON LF (ms2) 
Study 
groups 
n mean±SD Source of 
variation 
df Sum of 
squares 
Mean 
Square 
F 
value 
P value 
Group 
I 
10 159.8± 51.9 Between 
Groups 
2 57295.4 28647.7  
 
 
18.546 
 
 
 
0.000*** 
 
Group 
II 
10 90.9± 39.43 Within 
Groups 
27 41706.5 1544.69 
Group 
III 
10 54.4±19.7 Total 29 99001.9  
*** Highly significant P < 0.001 
Analysis  of  variance for  the effect  of  severity of  3 disease groups 
based on H&Y scale on LF(ms2) was  significant with the p value 0.000 
TABLE 19 ANALYSIS OF VARIANCE FOR THE SEVERITY OF 
DISEASE ON HF(ms2) 
Study 
groups 
n mean±SD Source of 
variation 
df Sum of 
squares 
Mean 
square 
F value P value 
Group 
I 
10 274.2±76.64 Between 
Groups 
2 150600 75300  
 
18.567 
 
 
0.000*** Group 
II 
10 161.3 ±69.97 Within 
Groups 
27 109501 4055.5 
Group 
III 
10 103.6±37.38 total 29 99001  
*** Highly significant P < 0.001 
It  is  obvious  that  there  was  a  significant  difference  among  the  
three   groups  from the  analyses  of  variance  for  the  effect  of  severity  of  
disease on HF (ms2).  
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TABLE 20 ANALYSIS  OF VARIANCE FOR THE SEVERITY OF 
DISEASE ON LF/HF RATIO 
Study 
groups 
N mean±SD Source 
of 
variation 
df Sum of 
squares 
Mean 
square 
F 
value 
P 
value 
Group 
I 
10 0.5922±0.136 Between 
Groups 
2 0.0084 0.0042  
 
0.1709 
 
 
0.84 Group 
II 
10 0.598±0.16 Within 
Groups 
27 0.6693 0.0247 
Group 
III 
10 0.5598±0.174 total 29 0.6778  
      P value < 0.05 significant 
It is clear from the above table that there was no significant 
difference observed among the three groups for LF/HF ratio. 
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6. DISCUSSION 
 This study was aimed at evaluating the autonomic nervous system 
activity using  Resting Heart Rate Variability and assessing the insulin 
resistance with serum insulin levels in Parkinson’s disease patients. 
Resting Heart Rate Variability was performed to assess the integrity of 
sympathetic and parasymapathetic division of Autonomic Nervous 
System and to assess the sympathovagal balance, and thereby to assess 
the prevalence and pattern of autonomic dysfunction in the Parkinsonism 
patients. Insulin resistance measured using serum insulin levels might 
show its role in the etiopathogenesis of Parkinsonism disease by 
accentuating neurodegeneration in predisposed individuals. 
6.1.  CHARACTERISTICS OF STUDY SUBJECTS 
 The mean age of Parkinson’s disease patients included in the study 
was 57 years who ranged from 48 years to 66 years. But, the mean age of 
Parkinson’s disease patients in the earlier studies  such as Dorji Hornod et 
al (2013)156, T.szili Torok et al107 (1999), T.H.Happaniemi et al (2001)108 
were  62.2 years, 66±7 years, 61.4 years respectively. Thus, the patients 
in the present study were in the age group lesser than the earlier studies. 
103 
 
Therefore, it could be stated that the changes in the Heart rate variability 
parameters are disease driven rather than age related.  
 The body mass index was calculated from the height and weight of 
the individual by the formula weight (kg)/ Height (m2). None of the 
subjects in both the group were obese. The mean BMI of the Parkinson’s 
disease group was 21.3 ± 1.71.  The mean BMI of the control group was 
22.08±1.68. The mean BMI of both the groups are not statistically  
significant so that it will not interfere with the dependent Heart rate 
variability variables according to Farah BQ Prado et al 2013 163. 
 The duration of disease in Parkinson’s disease patients included in 
this study was in the range between1 year to 16 years with the mean of 6 
± 4.64 years. 
According to Charlotte A et al (2007) 157, the incidence of 
Parkinsonism in women is lower and age of onset is higher. This is 
possibly due to increased physiological striatal dopamine levels resulting 
from the activity of estrogen. In the present study, the Parkinson’s disease 
patients were of almost equally distributed between sexes. Sexwise 
incidence of the disease was not seen. 
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6.2.  RESTING HEART RATE & BLOOD PRESSURE IN 
PARKINSON’S    DISEASE 
 The mean resting heart rate of the control was 78.03±5.91 and 
Parkinson’s disease group was 74±7.6. The mean of the resting heart rate 
in parkinsons patients is little lower than the control group but, was not 
statistically significant. According to Soares et al (2013) resting heart rate 
was higher in Parkinsonism patients but did not differ significantly. 
Increase in resting heart rate might indicate the cardiovascular risk at 
earlier stage. 
 Both the systolic and diastolic blood pressure at rest was lower in 
Parkinson’s disease group. The systolic blood pressure difference was 
highly significant (p value = 0.001) with mean systolic blood pressure of 
113.06±12.11 compared to 120.86±4.50 of controls. Similar findings 
were observed in Brevetti et al (1990) 159, Barbeau et al (1969) 160,  
Szili-Torok T et al (1999)107. 
 Brevetti et al (1990) 159 studied 24 hour blood pressure recording in  
Parkinson’s disease patients. In their study,  they recorded significantly 
low values of both systolic and diastolic blood pressure  in Parkinsonism 
illness. 
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 Barbeau et al (1969)160 revealed that blood pressure in Parkinson’s 
disease patients was usually lower than expected for age and sex which 
was resulting from diminished ability to secrete renin.  
 Gross et al (1972)158 also  demonstrated  that  in  patients  with  
Parkinson’s disease mean blood pressure was lower than that of controls. 
However, M.J.Aminoff et al (1975)161 reported contradictory findings 
stating that blood pressure was not low in Parkinson’s disease patients. 
 Parkinson’s disease is a progressive neurological disorder with 
pathological changes in the thalamus, corpus striatum, hypothalamic 
nuclei and brainstem reticular formation may lead to general lowering of 
both systolic and diastolic blood pressure. 
 In the present study, systolic blood pressure was significantly 
lower in Parkinson’s disease patients than the control group suggesting 
the sympathetic hypofunction of heart in accordance with Barbeau et al 
(1969). 
6.3.  RESTING HEART RATE VARIABILITY 
 The present study was carried out to record the early changes in 
Autonomic nervous system induced by Parkinsonism using resting Heart 
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Rate Variability. Hence, the Parkinson’s disease patients without any 
symptoms of autonomic dysfunction were enrolled for the study. 
  The Autonomic Nervous System is strongly influenced by 
sympathetic and vagus nerves. The resting Heart Rate Variability 
measurement signifies the autonomic tone. Under resting condition, 
cardiovascular  system  is  under  the  control  of  both  the  division  of  
Autonomic Nervous System. The extent of control by these two divisions 
varies from individual to individual. Spectral analysis applied to the   
inter beat interval has been considered as useful parameter for 
determining the Autonomic Nervous System functions. Heart rate 
variability is a valuable, non-invasive tool to assess the Autonomic 
Nervous System function. Any alteration in Heart Rate Variability is 
associated with the increased risk of adverse cardiovascular events. 
 Analysis of a Resting Heart rate Variability of 5 minutes recording 
done using the HRV analysis software, university of Kupio, version 1.1 
among both the study groups showed the following results. 
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6.4.  TIME DOMAIN MEASURES 
 Mean HR, Mean RR, SDNN, pNN50, RMSSD were the variable 
taken for the study as prescribed by the Task force. 
6.4.1. Mean HR & Mean RR 
 The Mean HR was not significantly lower than the control group as 
shown in the Soares et al (2013). The average mean HR of the 
Parkinson’s disease group was 72.33±6.8.Though these values are lower 
than the mean value obtained in normal subjects 76.8±6.04, but not 
statistically significant. The reduction in mean HR could be linked with 
the diminished baroreflex function as a result of vascular and cardiac 
sympathetic denervation in Parkinson’s disease patients (Santiago Perez 
et al 2013) 109. 
 The mean RR is the mean of the selected RR series. The average 
value of the mean RR was 0.790±0.07 which was not significantly more 
than when compared to controls. This finding is in accordance with Dorji 
Harnod et al (2014)156. In contrast Szili-Torok T et al (1999) 107 recorded 
that the average RR interval shorter in Parkinson’s disease patients. 
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6.4.2.SDNN  
 The SDNN is the standard deviation of Normal to Normal intervals 
which reflects the total power of spectral analysis. The mean value of the 
SDNN in Parkinson’s disease group was 52.06 ± 26.16 which was 
significantly lower (p = 0.03) when compared to normal subjects. This 
finding is in agreement with the values of Soares et al (2013) 162. The 
significantly reduced SDNN values  signifies the reduced HRV in 
Parkinson’s disease patients. 
6.4.2.  pNN50 
 In the present study, there was a reduction in pNN50 but not 
significantly. pNN50 was significantly less in Parkinson disease patients 
according to Soares et al(2013), M.Kallio et al (2000)100, Szili-Tork T et 
al(1999) 107. But, Van Dijik et al (1993)116 found no significant difference 
in pNN50 between Parkinson’s disease patients and controls. 
6.4.3. RMSSD 
 This is most commonly used measure derived from the differences 
of  NN  interval.  It  is  otherwise  defined  as  the  square  root  of  the  mean  
squared differences of the successive NN interval. RMSSD of short term 
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recording estimate High frequency variation in Heart rate and thus it is 
highly correlated with the HF. 
 The mean value of the RMSSD in our study in Parkinson’s disease 
group was 34.05±14.77 which was significantly lower (p=0.03) when 
compared to normal subjects. The above observation is in agreement with 
the RMSSD values recorded by Szilli-Torok et al(1999) 107,  Soares et al 
(2013) 162.However, M.Kallio et al (2000) 100 observed a reduction in 
RMSSD but do not differ significantly. 
 RMSSD, pNN50 are considered as sensitive indicator of 
parasympathetic function and thereby a low value indicates reduced vagal 
action. From the time domain measures, We observed a reduced Heart 
Rate Variability and reduced parasympathetic function in the present 
study.  
6.5.  FREQUENCY DOMAIN MEASURES OF HRV 
 Fast Fourier Transform method is followed in this study as it has 
the advantage of simple algorthims and a high processing speed. The 
power spectrum is commonly divided into ULF < 0.0033 Hz, VLF 
0.0033- 0.046 Hz, LF 0.004-0.15 Hz, HF – 0.15-0.4 Hz (Task Force 96). 
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6.5.1. LOW FREQUENCY POWER LF(ms2) 
 LF power component is primarily affected by sympathetic 
excitation and arterial pressure oscillation. The mean value of LF (ms2) 
obtained in the Parkinson’s disease patient was 101.7± 58.44 and that of 
control group was 171.033±97.6. The LF (ms2) is significantly reduced in 
the Parkinson’s disease group when compared to control group. This 
finding is in accordance with Dorji Hornard et al (2014)156, 
T.H.Haapaniemi et al (2001)112, Soares et al (2013)162,  Popisil  P  et  al  
(2008)104. The above findings support the sympathetic hyopfunction in 
the  Parkinson’s  disease  patients.  M.Kallio  et  al  (2000),  Van  dijik  et  al  
(1993) observed a low values of LF (ms2) but do not differ significantly. 
6.5.2.HIGH FREQUENCY POWER HF(ms2) 
This power spectral oscillation indicates only the parasympathetic 
nervous system (i.e.) cardio vagal modulation and inspiratory inhibition 
of vagal tone. The mean value of the HF (ms2) in the affected patients 
was 179 ± 94.7. These values are significantly lower than the values 
recorded in the normal subjects (266.13±170.74). The values are in 
agreement with the findings of Popisil P et al ( 2008)104,  Szili  –  Torok   
T et al (1999)107,M.kallio et al (2000)100, Soares et al (2013) 162who 
reported significantly low nalues of HF(ms2) in their studies. Dorji 
111 
 
Harnord et al (2014)156 concluded that parasympathetic variable is more 
likely affected in Parkinson’s disease patients. Van dijik et al (1993) 116  
observed no difference between control and Parkinson’s disease patients 
with respect to HF(ms2). T.H.Happaniemi et al (2010)108 recorded 
significantly low values of HF in th P value (0.004) in Parkinson’s 
disease patients which is associated with the severity of disease. 
6.5.3. LF/HF RATIO 
 LF/HF ratio, a noninvasive index of cardio sympathovagal balance 
is significantly decreased in this study. The LF/HF ratio obtained in 
Parkinson’s disease patient was 0.584±0.53 and that of control was 
0.719±0.26 with a p value of (0.01). Soares et al (2013)162 observed a 
significant reduction in LF/HF ratio in Parkinson’s disease patients 
reflecting the altered sympathovagal modulation in Parkinson’s diseas 
patients. M.Kallio et al (2000)100 found a significantly  low values of AR 
derived LF/HF ratio which revealed the evidence of Autonomic Nervous 
System regulation failure. Popisil P (2008)104 et al did not observe a 
significant difference in LF/HF ratio. 
6.5.4. TOTAL POWER 
 Total  power  in  the  HRV  is  a  sum  of  all  the  RR  interval  spectral  
powers ( Very low frequency, Low frequency, High frequency) in the 
112 
 
short term recordings. It is nothing but the variance of all NN intervals. It 
estimates the overall changes in the heart rate due to cycles shorter than 5 
minutes. 
 The mean value of the Total Power in Parkinson’s disease group 
was 312.5 ±154.8 which was significantly lower than the controls 
(482.3± 267.5). Popisil P (2008) 104 et al found a statistically high 
significant decrease of Total Power (438 VS 1238 ms2) in Parkinson’s 
disease patients. 
 Therefore, the analysis of frequency domain variables revealed a 
reduced HRV suggesting autonomic modulation in the form of both 
sympathetic and parasympathetic dysfunction in patients with 
Parkinson’s disease.  
 The neuropathology of Parkinson’s disease involves both the 
sympathetic and parasympathetic nervous system because lewy bodies 
and neurodgeneration have been seen throughout the central autonomic 
centres in the hypothalamus, locus ceruleus,dorsal vagal nucleus, nucleus 
ambigus as well as in the intermediolateral coloumn cells in the 
spinalcord and in the postganglionic sympathetic neurons in addition to 
the dopaminergic pathway. 
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 Thus, the cardiovascular dysregulation in Parkinson’s disease 
could be related to above central or peripheral neurophysiology resulting 
in both sympathetic and parasympathetic dysfunction which is also 
supported by the results in the present study. 
 Reduced HRV and significantly reduced low values of time 
domain and spectral HRV measures observed in the present study 
suggesting the involvement of ANS in the Pathophysiological process of 
Parkinson’s disease and these results are in accordance with the testing of 
other authors like Soares et al(2013)162, Popisil et al (2008)104, Dorji 
Harnord et al (2014)156. 
 Sympathetic hypofunction in Parkinson’s disease is supported by 
Turkka et al (1987)114 who  found  out  low  values  of   serum  nor  
epinephrine and its metabolite in Parkinson’s disease patients. Impaired 
myocardial uptake of meta – (123I) iodobenzylguanidine (MIBG) in 
MIBG myocardial scintigraphy favours loss of cardiac sympathetic nerve 
terminal and gives evidence for sympathetic hypofunction in Parkinson’s 
disease.(Goldstein DS, Holmes et al 1997)101 
 Presence of α-synuclein lewy bodies in dorsal vagal nucleus and 
higher centers cause parasympathetic nerve disturbances in Parkinson’s 
disease patients. In parkinson’s disease there is preponderance of 
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paraympathetically mediated disturbances has been shown by Piha et al 
1988164. 
 From the results, it is clear that both sympathetic and 
parasympathetic hypofunction is seen in Parkinson’s disease patients. 
Significant reduction in time and frequency domain of  HRV suggest that 
both sympathetic and parasympathetic influence on cardiac function are 
decreasing in Parkinson’s disease patients. The time domain measures of 
HRV showing significant reduction in RMSSD, SDNN values and 
significantly low values of HF (ms2) in the present study support reduced 
vagal action. It is obvious from the frequency domain measures showing 
significantly low values of LF (ms2) LF/HF ratio revealed sympathetic 
hypofunction. 
 Reduced HRV and reduction in HRV indexes could be associated 
with the pathophysiology of Parkinson’s disease and reflect loss of 
sympathetic and parasympathetic balance, which may be the result of 
neurodegeneration caused by Parkinson’s disease itself. 
 There exists a  close relation between autonomic dysregulation and 
the high mortality among the Parkinson’s disease patients. Therefore, a 
prospective examination of autonomic regulation using HRV in 
Parkinson’s disease might decrease cardiovascular risk and arrhythmia 
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related death in Parkinson’s disease patients.(T.Szilli- Torok et al 
(1999)). 
 Cardiovascular autonomic dysfunction is relatively a under 
recognized problem of Parkinson’s disease and it is closely associated 
with the progression of disease. Hence, the timely management  
of autonomic dysfunction might improve the patient’s life quality and  
life span.  
6.6. SERUM INSULIN LEVELS: 
  Serum insulin levels were measured using Accubind ELISA 
microwells Insulin Test System from the fasting blood samples. The 
mean value of the serum insulin levels in Parkinson’s disease patients 
was 9.22±3.48 and that of control was 7.49±3.22 which was statistically 
significant (p value 0.04).  The above values were in agreement with the 
findings of A.E.Boyd et al (1979)16 and Domenico Bosco et al (2012)74, 
Sandyk et al (1993)146. 
 The mean value of Fasting blood sugar in Parkinson’s disease 
group was 103.5±11.3 which did not differ significantly when compared 
with the normal subjects. (p value 0.08) 
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6.7.  INSULIN RESISTANCE (HOMA-IR) 
 HOMA-IR (Homeostatic Model Assessment of Insulin 
Resistance),  a widely used method to measure insulin resistance was 
followed in this study. The mean value of HOMA – IR in the Parkinson’s 
disease group was 2.30±0.70 which was significantly higher than the 
control group (1.71±0.61). 
 These results were in accordance with the findings of Domenico 
Bosco et al(2012)74 ,  Morris  JK  et  al  (2013)39. Domenico Bosco et al 
(2012) stated that insulin resistance was present in 62% of Parkinson’s 
disease patients of whom 36% had impaired glucose tolerance and 26% 
had only Insulin resistance. They concluded that there was significant 
positive correlation between Insulin resistance and Parkinson’s disease 
with dementia. 
 Morris JK et al (2013)39  found significant positive correlation 
between HOMA-IR values and dopamine depletion in both the substantia 
nigra and striatum in a preclinical model of Parkinson’s disease. He 
reported that peripheral insulin resistance would accentuate the 
neurodegeneration in Parkinson’s disease. 
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 Multiple hits like oxidative stress, mitochondrial dysfunction, 
neuroinflammation play a role in the neurodegeneration of Parkinson’s 
disease. Oxidative stress may be a connecting link between insulin 
resistance and neurodegeneration of Parkinson’s disease.  
According to M.Schaffer et al ( 1992 )134, Insulin acts as neuronal 
survival factor and protects against neuronal apoptosis. Moroo et al 
(1999)147 reported that Insulin receptor mRNA declines within the 
substantia nigra which coincides with the loss of tyrosine hydroxylase , a 
rate limiting enzyme in the dopamine synthesis. Hence, the dopaminergic 
neurons are affected in the Insulin resistance. 
 Morris JK et al (2013)39 suggested that Insulin resistance could 
make dopaminergic neurons in the substantia nigra more susceptible to 
toxic insults and exacerbate the process of neurodegeneration. Sandyk 
(1993) et al reported that impaired glucose tolerance out of insulin 
resistance may exacerbate the severity of illness and levodopa induced 
dyskinesia in Parkinson’s disease. 
 Hence, the coexistence of insulin resistance in Parkinson’s disease 
may increase their morbidity and progression of disease. Improvement of 
insulin sensivity and reduction of peripheral hyperinsulinemia through 
various measures like healthy diet, weight loss, aerobic exercise, drugs 
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may have beneficial effects in preventing or delaying the progression of 
Parkinson’s disease.  
6.8. CORRELATION OF VARIABLES 
 The negative significant correlation (p < 0.0001, r =-0.7519) was 
observed between LF (ms2) and duration of Parkinson’s disease. This 
finding is in accordance with the values of Dorji Harnod et al (2013) with 
a p value 0.04 and r = -0.364. 
 The negative significant correlation  (p < 0.00001 , r =- 0.7532) 
was observed between HF(ms2) and duration of disease. This finding is in 
agreement with the values of Dorji Harnod et al (2013) with a p value of 
0.04 and r=-0.356. 
 Hence, both LF (ms2)  and  HF  (ms2) showed significant negative 
correlation with the Parkinson’s disease duration in this study. However, 
LF/HF ratio , a global  indicator of sympathovagal balance showed a 
weak negative correlation with the Parkinson’s disease duration in this 
study which was not statistically significant. 
 Therefore, the reduced HRV and low LF (ms2)  and  HF  (ms2) 
values  correlated with the duration of Parkinson’s disease may be the 
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result of progressive neurodegeneration in the Parkinson’s disease 
patients with the longer duration . (Dorji Harnod et al 2013)156 
 Both Fasting serum insulin and the insulin resistance index (i.e) 
HOMA-IR values showed a weak, negative correlation with LF (ms2), 
HF (ms2)  and LF/HF ratio in this study. The reasons for not getting 
significant values could be attributed to small sample size covered in the 
study, variation among the diseased individuals. 
 However, the weak negative correlation coefficient for HRV 
variables and  HOMA- IR supports the effect of insulin resistance on 
autonomic dysfunction. This finding is in agreement with Domenico 
Bosco et al (2012)74 who found significant correlation between dementia 
and insulin resistance in Parkinson’s disease patients. This finding is also 
strengthened by Liao DP et al (1991)165 who stated that reduced HRV is 
associated with high insulin levels. 
6.9.  SEVERITY OF DISEASE WITH HRV VARIABLES 
 The patients classified into 3 groups according to the severity of 
disease showed significant variation in LF(ms2), HF(ms2) in this study 
with a p value < 0.000001. 
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 There was no significant differences in the LF/ HF ratio values 
among  the  three  groups  I,  II,  III  classified  according  to  the  severity  of  
disease based on H & Y scale. Therefore, the severity of disease has 
profound influence upon the LF(ms2), HF(ms2) values in this study. 
However, the severity of disease showed no significant variation in 
LF/HF ratio though it showed much reduction in the severe group. 
 Obtaining the non significant value in LF/HF ratio could be 
attributed to small sample size, various confounding factors like drug, 
BMI & others. 
 This finding is in agreement with Pospisil P et al (2008) 104who 
found a statistically decrease of Total Power, LF(ms2), HF(ms2) in the 
Parkinson’s disease patients with a advanced PD (H&Y =2.3) than in 
mild PD(H&Y=1.3). For them also, the change of LF/HF ratio was not 
statistically significant. 
 All these findings suggest autonomic dysfunction from the reduced 
HRV indices and elevated Insulin resistance index values in this study 
may have a role in the etiopathogenesis of Parkinson’s disease. A better 
understanding of the etiopathogenesis of Parkinson’s disease might help 
in the management of Parkinson’s disease and improvement of Patients 
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lifestyle and an early intervention may prevent the patients with 
Parkinson’s disease from adverse cardiovascular events.  
LIMITATIONS OF STUDY 
 The analysis of biochemical markers like Norepinephrine would 
have substantiated the autonomic dysfunction and their measurement 
could give valuable contribution to sympathetic hypofunction, which was 
not feasible in this study. 
 The confounding factors like drugs (eg . Levodopa, Selegilline) on 
Insulin resistance couldnot be avoided in this study. 
 Ultimately, an improved understanding of  the role of autonomic 
dysfunction and insulin resistance in Parkinsonism patients may help to 
treat effectively the patients and improve their lifestyle. 
 
 
  
122 
 
7.  CONCLUSION 
Resting Heart rate analysis performed in Parkinson’s disease 
patients have shown reduced HRV and both sympathetic and 
parasympathetic hypofunction in this study. This study concludes a 
reduced HRV from a  significantly lowered values of SDNN, Total power 
and LF/HF ratio in Parkinson’s disease group when compared to controls. 
In this study, sympathetic and parasympathetic impairement is supported 
by significantly decreased values of LF(ms2), HF(ms2) in Parkinson’s 
disease group. Autonomic dysfunction in Parkinson’s disease patients is 
significantly correlated with the Parkinsonian disease duration in this 
study. There is a significant difference found in the severe group 
according to H&Y scale with respect to LF(ms2),HF(ms2) in this study. 
The insulin resistance index values are significantly high in 
Parkinson’s disease patients when compared to controls. The prevalence 
of insulin resistance in Parkinson’s disease patients is more when 
compared with controls in this study.  Reduced HRV showed weak 
negative correlation with the insulin resistance in this study. 
Thus, the HRV could be a potential tool to screen for autonomic 
dysfunction in Parkinson’s disease patients and its timely management 
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might reduce adverse cardiac events in them. Insulin resistance could be a 
possible associated feature in Parkinson’s disease patients which has 
effective role in the pathophysiology of disease. 
Therefore, understanding the role of Autonomic nervous system 
and Insulin resistance in Parkinson’s disease patients might help in the 
management of disease and prevent complications and improve 
prognosis.                                                      
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8.  SUMMARY 
This study was performed to evaluate the autonomic function 
through resting Heart rate variability and to assess the role of insulin 
resistance in the pathogenesis of Parkinson’s disease using serum insulin 
levels in comparison with normal controls. 
 30 patients with Parkinson’s disease diagnosed as per Parkinson’s 
disease brain bank criteria and 30 normal subjects as controls were 
subjected to Resting Heart rate variability. The serum insulin levels were 
measured by ELISA method. Both time and frequency domain HRV 
parameters showed significant variation when compared with the normal 
subjects. It is clearly found from the analysis of data in this study that 
Parkinson’s disease patients had autonomic dysfunction with reduced 
HRV and both sympathetic and parasympathetic impairment, compared 
to their controls. The insulin resistance index values & fasting serum 
insulin levels were significantly higher in Parkinson’s disease patients. 
 Thus, the Parkinson’s disease patients are more prone for 
cardiovascular risk. Hence, the understanding of the role of autonomic 
dysfunction & associated Insulin resistance may help to prevent 
cardiovascular risk and the other complications of Parkinson’s disease. 
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Name and Signature of impartial witness (required for illiterate 
patients): 
 
Name _________________________ Signature_________________  
 
Date________________ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative 
obtaining consent: 
 
Name _________________________ Signature_________________  
 
Date________________ 
 
 
INFORMATION TO PARTICIPANTS 
Investigator:  Dr. S.P.Girijasivam. 
Name of Participant: 
Title: 
“A Study of Heart Rate Variability and serum Insulin level in 
patients with Parkinson’s disease” 
You are invited to take part in this research/ study /procedures. The 
information in this document is meant to help you decide whether or not 
to take part. Please feel free to ask if you have any queries or concerns. 
You are being asked to participate in this study being conducted in          
          Institute of Physiology and Experimental Medicine, 
          Madras Medical College and Govt. General Hospital, 
          Chennai - 3 
What is the Purpose of the Research? 
 Parkinson’s disease is a neurodegenerative morbidity that leads to 
motor, psychiatric and sleep disorder characterized by  motor symptoms, 
postural instability, shaking, rigidity, and slowness of movements . In 
addition to an extra pyramidal motor dysfunction, patients frequently 
show Autonomic Nervous System (ANS) disorders, even in early phases 
of the disease. Insulin resistance might potentiate the neurodegeneration 
in Parkinson’s disease. Insulin resistance measured using serum insulin 
levels. High insulin levels ,insulin resistance are  directly associated with 
autonomic dysfunction. 
We want to assess autonomic functions in Paarkinson’s disease 
patients and correlate the Insulin  levels with autonomic functions in 
Pakinson’s disease  thereby to find a new approach in the treatment of 
Parkinson’s disease. 
The Study Design 
Thirty  patients  with  Parkinson’s  disease   will  be  selected  for  the  
study. 
Study Procedures 
The study involves assessment of Heart rate variability and serum  
insulin levels. 
You will be required to visit the hospital once during the study. 
5ml of blood will be collected simultaneously during the study. Blood 
collection involves prick with a needle and syringe. 
In addition, if you notice any physical or mental changes, you must 
contact the persons listed at the end of the document.  
You may have to come to the hospital (study site) for examination 
and investigations apart from your scheduled visits, if required. 
Possible benefits to you- autonomic dysfunction can be diagnosed 
at an early stage so that proper intervention can be taken. 
Possible benefits to other people 
The result of the research may provide benefits to the society in 
terms of advancement of medical knowledge and/or therapeutic benefits 
to future patients.  
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your 
medical information (personal details, results of physical examinations, 
investigations, and your medical history). By signing this document, you 
will be allowing the research team investigators, other study personnel, 
sponsors, IEC and any person or agency required by law like the Drug 
Controller General of India to view your data, if required. 
The information from this study, if published in scientific journals 
or presented at scientific meetings, will not reveal your identity. 
 
How will your decision to not participate in the study affect you? 
Your decisions to not  to participate in this research study will not 
affect your medical care or your relationship with investigator or the 
institution. Your doctor will still take care of you and you will not loose 
any benefits to which you are entitled. 
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have 
the right to withdraw from this study at any time during course of the 
study without giving any reasons. 
However, it is advisable that you talk to the research team prior to 
stopping the treatment 
 
 
 
 
 
 
 
 
 
 
 
PROFORMA 
1. Name : 
2. Age: 
3. Sex: 
4. Address : 
5. Occupation : 
6. Duration of parkinsonism : 
 
7. History of Comorbid illness & duration : 
Diabetes  
Hypertension 
Ischemic Heart disease 
Cerebro vascular disease 
 
8. Symptoms of autonomic dysfunction: 
Giddiness on standing/near syncope 
Palpitation 
Abnormal/absence sweating 
Gastroperesis /GERD 
Bladder disturbances (retention, hesitancy, urgency, 
inconitence ) 
Bowel disturbances ( constipation , diarrhea) 
Loss of libido 
9. History of any drug intake & duration 
 
  
EXAMINATION 
General examination:   
  Height 
  Weight 
  BMI 
  Waist –hip ratio 
Pulse rate: 
Blood pressure:  
 Rt upper limb Lt upper limb 
Lying   
Sitting   
Standing   
 
Systemic examination: 
Cardiovascular system: 
Respiratory system: 
Gastrointestinal system: 
Central nervous system: 
 
INVESTIGATIONS: 
  Hb 
  Fasting Blood sugar, 
  Post prandial Blood sugar 
  Blood urea ,   Serum creatinine 
Fasting  serum Insulin  
 
HRV  VARIABLES 
 
FREQUENCY DOMAIN :         
LF power  
HF power 
LF/HF  ratio                                                                                                                              
TOTAL POWER 
TIME  DOMAIN  :    
   Mean HR   Mean RR 
SDNN   RMSSD 
NN50     pNN50 
 
 
 
 
 
 
 
 
 
 
SL NO AGE SEX BMI
RESTING 
HR
SBP 
RESTING
DBP 
RESTING
MEAN 
HR
MEAN 
RR
SDNN pNN50 RMSSD LF ms2 HF ms2
LF/HF
ratio
TOTAL 
POWER
FBS
FASTING 
INSULIN
HOMA-
IR
DURATION
H&Y
SCALE
1 66 M 18.42 62 110 70 58 1.012 96 42.6 56.6 139 326 0.426 520 106 10.2 2.66 2 1
2 64 M 21.64 72 100 70 64 0.942 26 5.6 23.4 106 158 0.67 282 113 4.2 1.71 6 3
3 63 M 20.06 80 118 74 80 0.746 48 20.6 35.5 115 196 0.586 331 94 9.6 2.22 4 1
4 62 F 22.86 74 110 70 73 0.839 34 6.6 40.6 62 183 0.338 338 96 14.7 3.48 7 3
5 67 M 20.25 84 120 70 92 0.652 28 1.2 22.5 38 142 0.267 217 102 12.3 3.09 16 4
6 59 F 22.37 76 126 80 65 0.961 24 6.2 24.6 126 174 0.724 322 89 8.2 1.8 1 1
7 54 M 18.31 68 106 70 80 0.746 102 53.6 60.1 31 51 0.607 85 99 9.1 2.22 15 4
8 48 M 22.39 64 122 70 63 0.951 63 21 22.4 56 60 0.933 131 118 4.9 1.42 12 3
9 60 F 20.2 80 100 70 70 0.862 68 2.6 16.2 109 168 0.648 391 96 7.3 1.73 1 2
10 43 F 19.74 78 130 90 72 0.848 26 1.8 15.8 46 72 0.638 138 118 6.4 1.86 14 4
11 58 M 21.34 83 120 80 65 0.961 62 24.8 24.7 58 108 0.537 178 97 10.2 2.44 9 3
12 61 M 19.61 82 90 60 88 0.688 64 7.9 23.6 102 233 0.437 372 86 18.3 3.88 2 2
13 57 F 21.34 72 130 80 62 0.962 54 43.2 58.2 168 298 0.563 492 93 10.2 2.34 2 1
14 54 F 21.88 74 116 78 76 0.819 101 34.6 40.2 48 103 0.466 163 89 12.3 2.7 13 4
15 59 M 24.56 80 130 80 60 0.981 62 21.4 42.1 238 279 0.853 538 99 3.2 0.78 2 1
16 53 M 22.22 82 120 64 74 0.868 26 1.4 16.8 166 362 0.458 572 106 12.2 3.19 2 2
17 65 M 23.05 90 90 70 84 0.71 58 30.6 30.6 74 126 0.587 209 119 7.8 2.29 5 4
18 52 F 20.83 64 100 70 59 1.001 68 8.2 61.5 43 159 0.27 216 88 16.4 3.56 7 4
19 58 F 21.33 66 120 70 65 0.961 26 8.4 26.6 116 190 0.61 363 94 10.2 2.36 3 3
20 55 M 23.14 70 100 70 60 0.981 32 2.8 51.9 86 158 0.544 268 116 9.9 2.83 2 3
21 53 M 20.9 72 110 70 73 0.839 44 1.5 32.7 61 77 0.792 178 113 6.9 1.92 11 4
22 55 F 23.88 84 106 70 72 0.848 28 8.7 40.2 248 366 0.677 632 120 6.9 2.04 1 2
MASTER   CHART   PATIENT 
SL NO AGE SEX BMI
RESTING 
HR
SBP 
RESTING
DBP 
RESTING
MEAN 
HR
MEAN 
RR
SDNN pNN50 RMSSD LF ms2 HF ms2
LF/HF
ratio
TOTAL 
POWER
FBS
FASTING 
INSULIN
HOMA-
IR
DURATION
H&Y
SCALE
23 50 M 24.38 70 108 70 86 0.698 64 56.4 52.1 82 127 0.645 233 118 6.6 1.92 8 4
24 57 M 20.7 64 90 70 68 0.882 56 30.4 23.1 103 196 0.525 334 107 10.1 2.66 4 3
25 60 M 20.31 76 120 80 90 0.678 38 10.2 30.6 43 58 0.741 113 97 7.3 1.748 9 3
26 52 M 23.46 70 120 70 78 0.788 25 1 16.3 177 280 0.632 485 99 11 2.68 3 3
27 54 M 18.26 80 120 80 64 0.941 122 60.2 19.6 85 122 0.696 275 103 4.1 1.042 5 4
28 58 M 19.72 81 120 80 76 0.819 40 9.6 21.3 102 222 0.459 355 93 10.3 2.36 2 3
29 51 M 21.79 75 110 70 90 0.678 44 9.2 55.6 36 57 0.631 102 121 6.2 1.85 10 4
30 62 F 20.07 74 130 90 63 0.942 33 11.4 36.2 187 340 0.55 542 116 9.9 2.83 2 2
BMI Body Mass Index 
HR Heart Rate
SBP Systolic Blood Pressure
DBP Diastolic Blood Pressure
SDNN Standard Deviation of NN Intervals
LF Low Frequency Power
HF High Frequency Power
FBS Fasting Blood Sugar
RMSSD Root Mean Square of the Standard Deviation  of NN Intervals
pNN50 Percentage of NN Interval differing by 50 milli seconds 
SL 
NO
AGE SEX BMI
RESTING
HR
RESTING 
SBP
RESTING 
DBP
MEAN 
HR
MEAN 
RR
SDNN pNN50 RMSSD
LF
(ms2)
HF
(ms2)
LF/HF
ratio
TP FBS
FASTING 
INSULIN
HOMA-
IR
1 52 M 22.66 82 118 74 63 0.951 103 38.2 79.3 128 187 0.684 370 97 6.3 1.5
2 54 M 20.57 76 126 70 70 0.824 42 14.4 16.8 240 229 1.049 587 68 7.9 1.32
3 55 M 21.68 82 124 80 76 0.802 32 11.6 29.1 133 451 0.295 642 97 5.4 1.29
4 53 F 20.46 81 124 84 72 0.806 67 22.8 52.7 132 120 1.095 289 107 7.8 2.06
5 50 F 24.68 79 116 76 68 0.91 58 20.6 77.1 85 112 0.761 212 113 5.4 1.5
6 55 M 21.05 74 114 68 80 0.704 96 31.8 30.8 277 348 0.795 669 80 12.2 2.4
7 59 M 23.12 78 124 76 70 0.823 114 38.6 16.8 43 59 0.729 111 73 11.1 2.01
8 57 F 22.43 81 110 70 80 0.746 54 17.2 17.4 323 416 0.776 801 86 9.4 1.99
9 56 M 25.97 96 124 76 72 0.806 41 14.6 37.9 188 308 0.610 550 118 5.4 1.57
10 58 F 21.22 74 120 80 81 0.714 116 29.4 70.1 72 76 0.946 156 122 4.2 1.27
11 45 M 20.74 80 122 78 74 0.823 110 24.6 26.3 71 95 0.747 187 92 11.3 2.56
12 48 M 23.11 60 124 84 70 0.862 64 21.2 36.2 145 153 0.946 330 83 10.2 2.09
13 42 F 22.31 70 124 80 76 0.787 142 46.8 75.5 423 551 0.770 1042 121 3.9 1.16
14 60 F 23.15 78 120 76 82 0.712 26 10.8 50.3 188 680 0.272 924 81 12.4 2.48
15 62 M 24.65 76 118 60 81 0.714 63 21.6 34.2 366 410 0.894 931 82 13.2 2.67
16 44 M 23.44 82 120 78 77 0.77 112 40.8 26.5 248 334 0.745 714 93 6.2 1.42
17 64 F 21.15 82 116 78 76 0.801 31 10.2 72.3 142 319 0.445 491 108 7.2 1.92
18 63 M 20.24 74 120 84 65 0.94 14 4.6 33.2 162 160 1.008 333 118 11.2 3.26
19 65 M 23.23 80 124 80 72 0.806 132 49.2 70.6 215 621 0.346 866 106 6.1 1.59
20 67 F 20.14 79 120 78 70 0.862 41 14.4 19.9 138 248 0.556 414 114 5.4 1.52
21 58 F 21.16 78 116 78 81 0.782 32 11.2 80.1 46 131 0.351 184 93 4.3 0.99
MASTER   CHART   CONTROLS
SL 
NO
AGE SEX BMI
RESTING
HR
RESTING 
SBP
RESTING 
DBP
MEAN 
HR
MEAN 
RR
SDNN pNN50 RMSSD
LF
(ms2)
HF
(ms2)
LF/HF
ratio
TP FBS
FASTING 
INSULIN
HOMA-
IR
22 54 M 22.25 81 118 80 78 0.883 66 22.6 16.3 199 201 0.992 456 117 3.3 0.95
23 56 M 24.02 80 120 78 71 0.859 35 14.8 33.2 87 79 1.101 277 99 4.6 1.124
24 52 F 19.23 79 128 78 81 0.71 70.6 24.6 70.5 61 66 0.920 144 108 5.4 1.44
25 59 M 22.38 78 128 74 74 0.823 46 16.2 60.3 247 433 0.494 712 106 4.4 1.151
26 61 F 23.24 80 126 74 72 0.848 90 24.2 30.2 237 221 1.070 479 114 3.2 0.9
27 53 M 20.24 79 124 76 75 0.81 122 40.8 16.5 72 214 0.337 300 81 9.7 1.94
28 57 F 19.76 68 112 74 71 0.859 31 10.4 74.3 237 269 0.878 538 79 10.2 1.98
29 64 M 20.15 81 124 78 80 0.746 33 11.8 30.1 44 77 0.534 129 80 13.2 2.60
30 54 M 24.03 73 122 72 75 0.814 139 46.8 60.6 182 416 0.438 631 83 4.2 0.86
BMI Body Mass Index 
HR Heart Rate
SBP Systolic Blood Pressure
DBP Diastolic Blood Pressure
SDNN Standard Deviation of NN Intervals
LF Low Frequency Power
HF High Frequency Power
FBS Fasting Blood Sugar
RMSSD Root Mean Square of the Standard Deviation  of NN Intervals
pNN50 Percentage of NN Interval differing by 50 milli seconds 
